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Probiotic lactic acid bacteria have been associated with a wide array of host-immune 
modulatory effects including down-regulation of pro-inflammatory gene transcription and 
expression following pro-inflammatory challenge, through direct and indirect contact 
with host immune cells. However, it is still unknown how many of these microorganisms 
convey these beneficial immune effects to the host. Lactobacillus rhamnosus R0011 and 
Lactobacillus helveticus R0389 were examined for their immunomodulatory activity on 
challenged human HT-29 and rat IEC-6 intestinal epithelial cells (IEC). Secreted 
products from both strains demonstrated the ability to down-regulate IL-8 production 
from challenged HT-29 with differential effects on CINC-1 production from challenged 
IEC-6 cells. Further, L. rhamnosus R0011-derived milk ferments were tested for their 
ability to modulate pro-atherogenic cytokine production from challenged human THP-1 
and U937 monocytes and macrophages. Culturing THP-1 and U937 macrophages with 
milk ferments resulted in the up-regulation of regulatory cytokine production in response 
to challenge with lipopolysaccharide indicating possible polarization into the regulatory 
M2b macrophage phenotype. Taken together, L. rhamnosus R0011 has been shown to 
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The Human Gut Microbiome 
The human gut microbiome encompasses every living microorganism within our 
gastrointestinal tract. The gut is a transient microenvironment influenced by diet, sex, and 
genetics (Mueller et al., 2006; Kovacs et al., 2011). With the advent of next-generation 
sequencing, it has been determined that each individual contains approximately 600,000 
unique microbial genes within the gastrointestinal tract (Guarner, 2015).  Under 
homeostatic conditions, the relationship between the gut microbiome and the host is 
mutualistic. These gut microbial symbionts aid in the digestion of many complex 
carbohydrates and fibres. The breakdown of these food stuffs leads to the production of 
many immunologically active metabolites such as short chain fatty acids (SCFAs). 
However, dysbiosis, or perturbations in the normal gut microbiota, has recently been 
associated with obesity, cardiovascular disease, and inflammatory bowel diseases 
(Carding et al., 2015).  
Members of the human gut microbiome have been identified as probiotics. 
Probiotics are defined as living organisms that when consumed in adequate amounts elicit 
certain health benefits to the host (FAO/WHO, 2001). These health benefits include gut 
pathogen antagonism, modulation of host immune responses, and enhancement of the 
structural integrity of the intestinal epithelial barrier within the host (Lebeer et al., 2010). 
In some cases, these microorganisms are already part of a healthy individual’s gut 
microflora. Although most of the health benefits elicited by probiotics are localized in the 




significant role in the systemic immune system (Smelt et al., 2012; Borchers et al., 2009; 
McCarthy et al., 2003; Moro-Garcia et al., 2012). 
The microorganisms within the gastrointestinal tract are in constant contact with 
the cells of the mucosal immune system and have been shown to beneficially modulate 
host immune responses by promoting physiological homeostasis through induction of 
regulatory cytokine production (Thomas and Versalovic, 2010). Further, through direct 
interactions with resident DCs, macrophages, and T cells within the gastrointestinal tract, 
these bacteria have been shown to have a role in the maturation of the naïve mucosal 
immune system (Hooper et al., 2012).  
The Mucosal Immune System 
Cells lining the mucosal surfaces of the gastrointestinal tract are in continual 
contact with both pathogenic and non-pathogenic bacteria. These intestinal epithelial 
cells (IECs) provide both a mechanical and chemical barrier that prevents these bacteria 
from entering systemic circulation (Artis, 2008). IECs are connected to one another 
through tight junctions providing a physical barrier which the normal gut microbiota and 
pathogenic bacteria cannot readily cross. Directly above these cells, there is a thick layer 
of glycosylated proteins known as the mucin layer. This mucin layer is produced by 
goblet cells along the gastrointestinal tract and provides additional protection from 
invading pathogens and commensal microorganisms (Sansonetti, 2004).  IECs also 
express a myriad of pattern recognition receptors (PRRs) which are used to recognise 
bacteria and other microorganisms. These include numerous toll-like receptors (TLR), 




proteins. If the mucin layer is breached, these PRRs become activated inducing IECs to 
produce pro-inflammatory cytokines and chemokines, such as interleukin-8 (IL-8), which 
act as potent chemoattractant proteins for neutrophils and other members of the immune 
system in order to maintain the structural integrity of the IEC layer (Pitman and 
Blumberg, 2000). 
Directly beneath the IEC layer there is a layer of connective tissue called the 
lamina propria containing numerous tissue macrophages, dendritic cells, and other 
members of the adaptive immune system such as T cells and B cells. Within the small 
intestine, there are also organised lymphoid structures which have been collectively 
called the gut-associated lymphoid tissues (GALT). The GALT is comprised of the 
Peyer’s patches, which are specialised lymphoid tissues containing high numbers of B 
cells, T cells, and antigen-presenting dendritic cells (DC). Directly above the Peyer’s 
patches are specialised epithelial cells called microfold cells (M cells).  M cells allow for 
the direct transport of dietary and microbial-associated antigens across the IEC layer into 
the underlying lymphoid tissues. DCs present within these tissues process antigens and 
present them to the surrounding T cells, optimising antigen-presenting cell, T cell and B 
cell interactions. Interestingly, these activated T and B cells can leave the Peyer’s patches 
via the mesenteric lymph node and provide protection at other systemic mucosal 
locations (Mowat and Agace, 2014).  
Depending on the antigen sampled, macrophages and DCs beneath M cells mount 
an appropriate immunological response. When this antigen is associated with a pathogen, 
there is a massive increase in pro-inflammatory cytokine, chemokine, and antibody 




the invading pathogen. However, once the invading pathogen or danger signal is cleared, 
the inflammatory signal is terminated and there is an increase in the transcription of 
regulatory cytokines in an attempt to return to physiological homeostasis (Barton, 2008). 
Although inflammation plays an important role in host defence, continuous expression of 
these inflammatory biomarkers is associated with the pathogenesis of several chronic 
inflammatory diseases (Manabe, 2011). 
The Innate Immune System 
 The innate immune system is the first line of defense against invading 
microorganisms. Unlike the adaptive immune system, innate immunity is characterised 
by a general, non-specific inflammatory response to invading microorganisms with no 
immunological memory (Janeway and Medzhitov, 2002). Cells of the innate immune 
system distinguish between self and non-self by recognizing microbe-associated 
molecular patterns (MAMPs) and pathogen-associated molecule patterns (PAMPs) on the 
surface of invading microorganisms through PRRs (Kumar et al., 2011; Takeda and 
Akira, 2015). Once recognized, these cells invoke an inflammatory response through the 
production of cytokines and chemokines. Cytokines are small, soluble proteins secreted 
by activated cells which elicit an effect on nearby cells (and sometimes have autocrine or 
long range effects). Chemokines are chemoattractant proteins with a major role in 
controlling homing and migration of immune cells. Once secreted, cytokines and 
chemokines attract other members of both the innate and adaptive immune systems in an 




PRRs include the TLRs and the NOD proteins.  To date, there have been 13 TLRs 
identified in mammals, each recognizing a different, unique MAMP (Pandey et al., 
2015). These PRRs are present on both the cell surface and within the intracellular 
environment of innate immune cells. For example, toll-like receptor-4 (TLR-4), present 
on the surface of many members of the innate immune system, recognises 
lipopolysaccharide (LPS), the major constituent of the outer membrane of Gram-negative 
bacteria. Toll-like receptor-5 (TLR-5), also present on the surface of many cells, 
recognises bacterial flagellin, while toll-like receptor-3 (TLR-3), an intracellular TLR, 
recognises double-stranded RNA (Takeda and Akira, 2015). Once bound, these TLRs 
induce a signalling cascade through the recruitment of several adaptor molecules 
including myeloid differentiation factor 88 (MyD88), TIR domain-containing adaptor-
inducing interferon-β (TRIF), and TRIF-related adaptor molecule (TRAM). Interestingly, 
these TLRs use different combinations of these adaptor molecules in order to elicit 
different cellular responses. For example, TLR-4 utilizes both MyD88 and the MyD88-
independent TRIF/TRAM pathways to induce the activation of different transcription 
factors (Pandey et al., 2015). These intracellular signal cascades terminate with the 
activation of the Nuclear Factor-κB (NF-κB) transcription factor, the interferon 
regulatory factors (IRF), the activator protein (AP-1) family of proteins, or the mitogen-
activated protein kinases (MAPKs) (Pandey et al., 2015). Activated transcription factors 
induce the transcription of numerous pro-inflammatory cytokines and chemokines. 
Unlike the TLRs, NODs are solely intracellular PRRs which recognize peptidoglycan 
motifs present on both Gram-positive and Gram-negative bacteria. Once activated, these 




activation of the NF-κB transcription factor and the increased transcription of pro-
inflammatory cytokines and chemokines. Inflammasomes contain intracellular PRRs 
which respond to PAMPs and damage-associated molecular patterns (DAMPs) such as 
extracellular adenosine triphosphate (ATP). These inflammasomes often contain a 
member of the NOD family of proteins and activation of these PRRs results in the 
induction of caspase-1, an enzyme responsible for the cleaving of pro-interleukin-1β (IL-
1β) to the biologically active, pro-inflammatory IL-1β. 
 Within the innate immune system, there are a number of cells each with their own 
unique repertoire of PRRs to recognize specific MAMPs and PAMPs. The majority of 
these cells are derived from the bone marrow. These pluripotent hematopoietic stem cells 
give rise to a common myeloid progenitor which can further differentiate into 
granulocytes and monocytes. Granulocytes are characterised by granules in their 
cytoplasm and give rise to monocytes, neutrophils, eosinophils, and the basophils 
(Janeway and Medzhitov, 2002). Monocytes are circulating sentinels of the innate 
immune system which differentiate into tissue macrophages upon stimulation with 
specific cytokines and chemokines or pathogens. Once differentiated, these macrophages 
are tasked with scavenging, pathogen recognition and elimination, and antigen 
presentation to the adaptive arm of the immune system (Janeway and Medzhitov, 2002).   
Atherosclerosis and the Innate Immune System 
Cardiovascular disease (CVD) has become the leading cause of death globally, 
accounting for approximately 30% of all deaths worldwide and 48% of all deaths which 




contributing to CVD are hypertension, diabetes, smoking, poor diet, underlying 
autoimmune disease, and previous infections with pathogens (Rosenfield and Campbell, 
2011; WHO, 2011). The most frequent underlying cause of CVD is atherosclerosis 
(WHO, 2011). Atherosclerosis is a disease which affects both large and mid-sized 
arteries, resulting in the formation of plaques (lesions). Although this disease progresses 
silently for years, it can ultimately result in myocardial infarction, ischemic stroke, 
ischemic damage to kidneys and intestines, and other life-threatening events due to 
plaque rupture (Libby et al., 2013; Lusis, 2000). Traditionally, it was believed that 
atherosclerosis resulted solely from the buildup of cholesterol in the arterial wall.   
Understanding of this process has changed as the underlying mechanisms behind the 
development of plaques have become better understood and a role for inflammation has 
been recognised. More recently, both the innate and adaptive arms of the immune system 
have been implicated in the pathogenesis of this disease (Libby et al., 2011). 
Atherosclerotic plaques are initiated through the accumulation of apolipoprotein 
B (apoB)-containing low density lipoproteins (LDL) within the endothelial cell layer of 
arteries (the barrier between blood and tissues) in areas of low shear stress (Tabas et al., 
2007; Skalen et al., 2002; Zand et al., 1999). It is thought that these LDLs bind to 
proteoglycans present within the subendothelial space via an ionic interaction between 
the apo-B100 moiety on the surface of LDLs and the negatively charged sulphate groups 
present on the proteoglycans (Boren et al., 1998). Once bound, these LDLs undergo a 
variety of oxidative modifications (oxLDL), primarily due to the activity of lipoxygenase 
enzymes and reactive oxygen species (Cyrus et al., 1999). These oxLDL molecules 




leukocyte adhesion molecules such as P-selectin, vascular cell adhesion molecule-1 
(VCAM-1) and intercellular adhesion molecule-1 (CD54/ICAM-1) (Cominacini et al., 
1996; Khan et al., 1994).  Adhesion molecules are expressed on the surface of the 
endothelial cells and facilitate the binding of migrating leukocytes. Further, these 
activated endothelial cells secrete chemokines, such as monocyte chemotactic protein-1 
(MCP-1) and chemokine (C-C motif) ligand 5 (CCL5/RANTES) (Gautier et al., 2009). 
Travelling monocytes are directed towards the activated endothelial cell layer where they 
bind to P-selectin on the surface of the endothelial cells and ultimately adhere via binding 
of leukocyte function-associated molecule-1 (LFA-1) and very late antigen-4 (VLA-4) 
(expressed on the travelling monocytes) to CD54/ICAM-1 and VCAM-1, respectively 
(Legein et al., 2013; Ley et al., 2007; Mestas and Ley, 2008). Monocytes eventually 
traverse the endothelial cell layer into the intima (the area between the endothelial cell 
layer and smooth muscle cells) through diapedesis. Once inside the intima, monocytes 
secrete lipoprotein-binding proteoglycans, further perpetuating the accumulation of LDL 
and monocyte accumulation at the activated endothelium (Legein et al., 2013). 
Monocytes which have migrated across the endothelial cell layer into the intima 
eventually become differentiated into macrophages through the activity of macrophage 
colony-stimulating factor (M-CSF) (Moore and Tabas, 2011). These differentiated 
macrophages exist as a heterogeneous population consisting of M1 and M2 cell 
populations in atherosclerotic plaques (Legein et al., 2013). M1 macrophages, also 
known as classical macrophages, are activated by TLR recognition of conserved PAMPs 
such as LPS and peptidoglycan. Once activated, M1 macrophages produce inflammatory 




interleukin-12 (IL-12) (Moore and Tabas, 2011). Prolonged M1 macrophage activation 
can potentially lead to tissue damage and impair wound healing (Legein et al., 2013). In 
contrast, M2 macrophages are activated by parasite antigens and cytokines secreted by T-
helper 2 (Th2) cells such as interleukin-4 (IL-4) and interleukin-13 (IL-13) (Moore and 
Tabas, 2011). Unlike M1 macrophages, M2 macrophages have been shown to produce 
regulatory cytokines such as interleukin-10 (IL-10), interleukin-1 receptor antagonist (IL-
1Ra), and transforming growth factor-β (TGF-β) and mediate tissue healing through the 
secretion of collagen (Legein et al., 2013; Moore et al., 2013). In human atherosclerotic 
plaques, both M1 and M2 macrophages are present (Stoger et al., 2012; Johnson et al., 
2009). However, macrophages displaying the M1 phenotype are the dominant cell 
phenotype in progressing atherosclerotic plaques (specifically areas within the plaque that 
are prone to rupture) (Khallou-Laschet et al., 2010). In experimental models which 
reverse the progression of the atherosclerotic plaque, M1 macrophages undergo a 
phenotype switch to M2 macrophages indicating a significant role for M1 macrophages 
in the inflammation associated with atherosclerosis (Feig et al., 2011). 
Once differentiated, both M1 and M2 macrophages begin to take up oxLDL 
through the scavenger receptors SRA (scavenger receptor type A) and CD36 (Legein et 
al., 2013). Once inside the intracellular environment, the oxLDL release cholesterol. 
These cells can also take up unmodified LDL through micropinocytosis (Libby et al., 
2013). This massive increase in oxidized lipid influx and subsequent cholesterol release 
overwhelms the cell’s ability to remove these molecules resulting in the formation of 
macrophage foam cells (Legein et al., 2013). Eventually, these cells die and lead to the 




Accumulating necrotic bodies, coupled with the inability to efficiently remove the 
necrotic debris, are thought to contribute to plaque size and promote plaque progression 
(Moore and Tabas, 2011). 
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1This is a non-comprehensive list of macrophage phenotypes present within 
atherosclerotic plaques 
Other cells of the immune system implicated in atherosclerosis pathology are 
dendritic cells (DCs) (Bobryshev, 2005), which are professional antigen-presenting cells 
responsible for activating and facilitating the cross-talk between the innate and adaptive 
arms of the immune system. As is seen with macrophages, there is a heterogeneous cell 
population of different dendritic cells in atherosclerotic plaques (Legein et al., 2013). 
Dendritic cells are also involved in the uptake of oxLDLs which increases antigen 
presenting efficacy to T cells (Alderman et al., 2002). Further, DCs produce cytokines 
which actively recruit T cells to the atherosclerotic plaque. T cells, or those lymphocytes 
with the characteristic T-cell receptor (TCR) on their surface, migrate to the growing 
atherosclerotic plaque in a similar fashion to monocytes (Legein et al., 2013). It is 




the surface of LDLs (as mentioned above); however this is still under investigation 
(Legein et al., 2013). Once activated, these cells elicit a wide range of responses, 
including the production of pro-inflammatory cytokines further perpetuating the 
development of the atherosclerotic plaque. 
Recently, TLRs have been implicated in the pathogenesis of atherosclerosis 
(Libby et al., 2013; Cole et al., 2013). For example, TLR-4 has been implicated in 
increasing macrophage differentiation into foam cells by increasing oxLDL uptake in the 
presence of LPS (Howell et al., 2011). In fact, the cell-surface expression of TLR-4 on 
macrophages and endothelial cells is significantly higher in human atherosclerotic 
plaques than in normal arteries suggesting that this receptor may play an important role in 
the development of atherosclerosis (Edfeldt et al., 2002).  As such, it has become 
increasingly evident that these innate pattern recognition receptors may play an integral 
role in the development of atherosclerosis. 
Probiotic-Derived Fermented Dairy Products and their Effect on the Human 
Immune System and CVDs 
Dairy products, including milk, yogurt, and cheese, are major constituents of the 
North American and European diet. Historically, consumption of milk and other dairy 
products was closely associated with an increase in both serum cholesterol levels and 
incidence of stroke in epidemiological studies (Appleby et al., 1999; Larsson et al., 
2009). However, these claims have been refuted by multiple studies suggesting 
consumption of dairy products protects against cardiovascular disease and may modulate 




These effects on host immune responses are largely attributable to bioactive proteins 
present within milk such as lactoferrin, immunoglobulins, and growth factors (Chatterton 
et al., 2013). For example, β-lactoglobulin and α-lactalbumin, two major proteins found 
within bovine whey, up-regulate the production of IL-1Ra in human neutrophils through 
a NF-κB-dependent mechanism (Rusu et al., 2009). 
Many of the organisms defined as “probiotic” belong to the Gram-positive lactic 
acid-producing family of bacteria (Naidu et al., 1999) and have been used in dairy starter 
cultures for milk fermentation since ancient times. It was hypothesized in 1907 by Élie 
Metchnikoff that dairy products fermented with lactic acid bacteria confer health benefits 
to the host (Metchnikoff, 1907). Since then, there has been extensive research examining 
Metchnikoff’s health claims (Shiby et al., 2013). These health-related effects include the 
down-regulation of pro-inflammatory cytokines in IEC, antioxidant activity, alleviation 
of food allergies and sensitivities (including improved lactose tolerance), alleviation of 
antibiotic-induced diarrhea, and antagonism of gut-associated pathogens (Parvez et al., 
2006; Wagar et al., 2009; Virtanen et al., 2006). Recent evidence has also suggested that 
the consumption of fermented milk products can change host metabolism of certain food 
stuffs and even reduce social anxiety in humans (McNulty et al., 2011; Hilimire et al., 
2015). 
Lactic acid bacteria primarily convert lactose into lactic acid during milk 
fermentation. Some of these bacteria concurrently secrete proteases which release 
bioactive peptides from milk proteins (casein and whey) and some synthesize vitamins 
such as A and E (Beermann and Hartung, 2013). The bioactive peptides released during 




antihypertensive (through the inhibition of the angiotensin-converting-enzyme) and 
antioxidant properties (Beermann and Hartung, 2013). Other fermentation products have 
also been associated with anti-hypertensive attributes. For example, the consumption of a 
dairy product high in gamma-aminobutyric acid (GABA), a product of bacterial 
fermentation, was shown to significantly lower blood pressure in patients suffering from 
mild hypertension (Inoue et al., 2003). It has also been shown in a double-blind 
randomised clinical trial that a yogurt formulation with L. reuteri NCIMB 30242 
significantly reduced serum cholesterol levels in hypercholesterolemic adults (Jones et 
al., 2012). Further, there was a 15% reduction in cardiovascular disease risk seen in 
subjects consuming fermented dairy products when compared to those subjects consumed 
non-fermented milk (Sonestedt et al., 2011). Collectively, these observations suggest that 
fermentation of milk with select lactic acid bacteria increases the nutritional value of the 
milk prior to consumption and may improve cardiovascular health.  
Probiotic-Derived Secreted Bioactive Molecules  
 Traditionally, it was believed that in order to confer their immunomodulatory 
benefits, probiotic microorganisms had to interact directly with IECs and other parts of 
the immune system. Recently, there has been a growing body of scientific literature 
suggesting that these bacteria also secrete an array of bioactive molecules having 
immunomodulatory activity. Bioactive molecules include short-chain fatty acids, 
lipoteichoic acid, adenosine triphosphate, tryptophan metabolites, and lactocepins and 
other secreted proteins. These secreted molecules retain their biologically active 
properties following intestinal transport through the IEC layer in the GI tract and may 




Short-Chain Fatty Acids 
 As mentioned previously, one of the major metabolites of bacterial fermentation 
of dietary fibres in the gut are SCFAs including lactic acid, acetic acid, propionic acid, 
and butyric acid. However, acetic acid, propionic acid, and butyric acid are the 
predominant bacterially-derived fermentation products within the gut. These SCFAs have 
been associated with many immunomodulatory activities including decreased pro-
inflammatory cytokine and chemokine transcription and decreased leukocyte recruitment 
to inflamed tissues through the modulation of cellular adhesion molecules (Vinolo et al., 
2011). SCFAs bind to the G-protein coupled receptors, GPR41 and GPR43, which are 
expressed by IECs, adipose tissue, and cells of the immune system (Kimura et al., 2014). 
 Butyric acid, the most widely studied of the SCFAs, is the predominant energy 
source for colonocytes. It has been shown to have numerous immunomodulatory 
activities which are largely attributed to its ability to act as a histone deacetylase 
inhibitor. This leads to the decreased transcription of many pro-inflammatory cytokines 
and chemokines (Sanderson, 2004).  
 Lactic acid is the major metabolite produced during the fermentation of milk by 
lactic acid bacteria. It exists in two optical isomers, L(+)- and D(-)-lactic acid. The ratio 
between the two isomers within cultures depends on the microorganism used for 
fermentation. Lactic acid has immunomodulatory activity by suppressing the production 
of pro-inflammatory cytokine production, proliferation and cytotoxic activity of cytotoxic 






 Lipoteichoic acid (LTA) is a major constituent of the cell walls of Gram-positive 
bacteria and regulates the activity of cell wall hydrolases involved in bacterial cell 
replication. LTAs typically contain a glycolipid anchor with a hydrophilic tail containing 
1,2-phosphodiester-linked polymers of glycerol-phosphates. These glycerol-phosphates 
can be substituted with D-alanyl or sugar residues (Neuhaus and Baddiley, 2003). LTA 
can be liberated and secreted by certain Gram-positive bacteria during replication or 
bacteriolysis caused by β-lactam antibiotics (Ginsburg, 2002). Once liberated, it is 
recognised by members of the innate immune system through toll-like receptor-2 (TLR-
2) with CD14 and CD36 acting as co-receptors. The traditional view has been that once 
LTA binds to TLR-2, there is an increase in the transcription of the pro-inflammatory 
cytokines IL-1, IL-5, IL-6, and IL-8 (Ginsburg, 2002). However, recent research has 
indicated that the immunogenic properties of LTA are species-dependant, and vary 
depending on certain structural features of LTA (Lebeer et al., 2012). For example, LTA 
isolated from Staphylococcus aureus is highly immunostimulatory, resulting in the 
increased transcription of many pro-inflammatory cytokines including TNF-α (Schröder 
et al., 2003). In contrast, LTA isolated from Lactobacillus plantarum down-regulates 
TNF-α induced pro-inflammatory cytokine transcription in vitro. This inhibition was 
mediated through a TLR-2 dependant mechanism and resulted in the inactivation of the 
NF-κB signalling pathway (Kim et al., 2012). Further, LTA isolated from L. plantarum 
was attributed with the ability to down-regulate LPS-induced inflammation in vitro and 
atherosclerotic plaque formation in vivo in ApoE-/- mice by modulating the expression of 




differences in immunostimulatory capacities of different LTA molecules are often the 
result of sugar substitutions or replacement of D-alanyl moieties with L-alanyl within the 
hydrophilic tail (Lebeer et al., 2012).  
Adenosine Triphosphate 
Adenosine triphosphate, a nucleoside triphosphate involved in energy transfer 
within the cell, has recently been identified as an important mediator of the immune 
response (Trautmann, 2009). Extracellular ATP (eATP) has now been identified as a 
DAMP which is released by cells that are under physiological stress. Once released, 
eATP often triggers inflammatory immune responses acting through the P2Y purinergic 
receptors expressed by immune cells. This inflammatory immune response involves the 
increased transcription of pro-inflammatory cytokines and cell-adhesion molecules. In 
fact, eATP can also act as a chemotactic molecule recruiting white blood cells towards 
sites of tissue stress (Di Virgilio and Vuerich, 2015).  
eATP can be hydrolysed into adenosine through the activity of membrane-bound 
enzymes. CD39, or ecto-nucleoside triphosphate diphosphohydrolase 1, catalyses the 
conversion of ATP to adenosine monophosphate (AMP) and CD73, or ecto-5’-
nucleotidase, dephosphorylates AMP into adenosine. These enzymes are constitutively 
expressed on the surface of many cells of the immune system and their activity is dictated 
by the local environment (Antonioli et al., 2013).  
Liberated adenosine can bind to immune cells through the A2A adenosine 
receptor resulting in an increase in the intracellular concentration of cyclic-AMP 




response element binding protein (CREB) by protein kinase A (PKA). This ultimately 
results in the decreased activity of NF-κB and subsequent transcription of pro-
inflammatory mediators (Gerlo et al., 2011).  In inflammatory conditions or when the 
levels of eATP are high, CD39 and CD73 rapidly convert the pro-inflammatory ATP into 
the immunoregulatory adenosine. In fact, decreased expression of these enzymes is 
associated with the pathogenesis of many chronic inflammatory conditions including 
atherosclerosis (Antonioli et al., 2013). 
Recent evidence has suggested that some species of gut-associated bacteria can 
secrete ATP into the extracellular environment when grown in glucose-rich medium 
(Hironaka et al., 2013). Although it is still unclear if these bacteria secrete ATP in order 
to facilitate cross-talk within the host, commensal-derived ATP drives the differentiation 
of Th17 cells within the lamina propria (Atarashi et al., 2008).  
Tryptophan Metabolites 
Dietary tryptophan can be metabolized in the gut lumen by Lactobacilli which 
convert tryptophan into indole. Indoles have recently garnered attention as they have 
been implicated in modulating host immune responses. Bacterially-derived indoles bind 
to aryl hydrocarbon receptors (AHR) present in immune cells within the GALT (Esser et 
al., 2009). AHRs are intracellular receptors predominantly found within cells lining the 
skin, lungs, and the gastrointestinal tract. They are responsible for recognizing and 
binding small molecular weight endogenous and exogenous molecules, such as serotonin 
and tryptophan metabolites (Noakes, 2015). Once bound, the AHR translocates to the 




in xenobiotic metabolism or interacting with other signalling pathways such as the NF-κB 
signalling pathway suggesting a role of the AHRs in inflammation (Vogel et al., 2014). 
Indoles produced by Lactobacilli induce the production of interleukin-22 (IL-22) in 
innate lymphoid cells (Zelante et al., 2013). IL-22 belongs to the IL-10 superfamily and 
is involved in the initiation of the immune response against invading pathogens 
(Dumoutier et al., 2000).  The induction of IL-22 was mediated by the binding of indole-
3-amine to the aryl hydrocarbon receptor (Zelante et al., 2013) 
Endogenous tryptophan metabolites can also activate the AHRs leading to 
modulation of inflammatory processes within the cell. Tryptophan is primarily 
metabolised through the kynurenine pathway via the indoleamine 2,3-dioxygenase (IDO) 
enzyme (Noakes, 2013). This enzyme has also been implicated in having a role in the 
pathogenesis of atherosclerosis (Polyzos et al., 2015). Interestingly, some Lactobacilli 
modulate the expression of IDO and subsequent tryptophan metabolism in vitro. H2O2 
produced by Lactobacillus johnsonii significantly inhibited the activity of IDO in HT-29 
IECs in vitro (Valladares et al., 2013). 
 Bacteriocins  
 Bacteriocins are small (less than 10 kDa in size), antimicrobial peptides produced 
by many lactic acid bacteria. These antimicrobial peptides are heat-stable and active in 
acidic environments (pH less than 5) (Jack et al., 1995) and inhibit the growth of several 
gut-associated pathogens in vitro and antagonise the adherence of gut pathogens to IECs 
in vivo (Hudault et al., 1997; O’Shea et al., 2012).  It is believed that these molecules 




ultimately leading to bacterial cell death (Nes and Holo, 2000; Diep et al., 2007). For 
example, a bacteriocin produced by Lactobacillus plantarum KLDS1.0391 was shown to 
disrupt the membrane potential of S. typhimurium cells leading to the release of ATP, 
potassium ions, and other integral intracellular components (Gong et al., 2010).  
Lactocepins and other Secreted Molecules 
 Lactocepins are biologically active proteases that can be secreted or anchored to 
bacterial outer cell membranes. They were first identified in Lactococci species and have 
since been identified in Lactobacilli. These proteases have the ability to degrade casein to 
liberate free amino acids required for bacterial cell growth during milk fermentation. 
Recently, a novel role for some lactocepins has been identified. A lactocepin produced by 
Lactobacillus paracasei selectively degraded the pro-inflammatory IP-10 chemokine 
produced by IECs in a clinically induced mouse colitis model. This led to the abrogation 
of cecal tissue inflammation and to reduced infiltration of lymphocytes in the inflamed 
tissue (von Schillde et al., 2012). 
 Other Lactobacilli secreted proteins have also garnered attention for their anti-
inflammatory activity. Most notably, p75 and p40, secreted by Lactobacillus rhamnosus 
GG have been shown to reduce cytokine-induced epithelial cell damage in both human 
and mouse colonic epithelial cells. These proteins are cell wall hydrolases with 
endopeptidase activity which are responsible for normal separation of L. rhamnosus GG 
cells during replication (Claes et al., 2012).  It was determined that these proteins 





 N-formyl peptides (fMLF) are bacterially produced peptides which contain the N-
formyl methionine amino acid. fMLFs are produced by both pathogenic and commensal 
bacteria and have been recently been found to bind to formyl peptide receptors (FPR) 
present on cells of the innate immune system. Once bound, these receptors induce the 
transcription of pro-inflammatory cytokine and chemokine production and reactive 
oxygen species (ROS) generation (Migeotte et al., 2006). fMLFs produced by L. 
rhamnosus GG have recently been shown to up-regulate ROS production in IECs 
(Wentworth et al., 2011). This increase in ROS production at the IEC level has been 
shown to down-regulate pro-inflammatory cytokine transcription by inhibiting NF-κB 
activation and promote intestinal barrier function (Kumar et al., 2007; Lin et al., 2009; 
Alam et al., 2014).  
Potential Mechanisms of Action of Probiotics 
 The molecular mechanisms of action behind many of the observed beneficial 
effects of probiotics on the host immune system have remained elusive. However, there 
has been considerable attention spent examining gene alteration involved in the negative 
regulation of the NF-ĸB signalling pathway in response to probiotic treatment including 
the up-regulation of the A20 and the peroxisome proliferator-activated receptors (PPAR) 
family of proteins. 
A20 (TNFAIP3: Tumour Necrosis Factor α-Induced Protein 3) 
The A20 protein is responsible for the termination of the pro-inflammatory NF-
κB signalling pathway and TNF-α induced apoptosis. Activation of the NF-κB pathway 




protein has recently emerged as a potential marker in the pathogenesis of several 
immune-related disorders as small loss-of-function mutations in the gene locus encoding 
this protein have been associated with inflammatory diseases such as Crohn’s disease, 
rheumatic heart disease, and atherosclerosis (Vereecke et al., 2009). In most cell types, it 
is not constitutively expressed as it is a NF-κB target gene. Therefore, A20 expression is 
dependent upon stimulation via the TLR, IL-1R, NOD receptors, or TNF-receptor (TNF-
R) pathways. Once expressed, A20 antagonizes a variety of molecular targets in the NF-
κB signalling pathway (dependent upon which receptor was activated) in an attempt to 
regulate the cell’s response to pro-inflammatory stimuli and allow the cell to return to 
homeostatic conditions. These molecular targets include: TNF receptor associated factor-
6 (TRAF-6) in response to TLR and IL-1R stimulus, receptor-interacting serine/threonine 
kinase -2 (RIPK-2) in response to NOD stimulus, and receptor-interacting 
serine/threonine kinase-1 (RIPK-1) in response to TNF-R stimulus (Ma and Malynn, 
2012). Once bound, the A20 protein effectively terminates any subsequent signalling 
induced by the activation of the aforementioned receptors blocking the activation of NF-
κB. 
As mentioned previously, inflammation has been implicated in the pathogenesis 
of atherosclerosis. As such, much attention has been focused on examining the potential 
role of the negative regulators of the immune system, such as the A20 protein, during the 
development of atherosclerosis. In an experiment conducted using atherosclerosis-
sensitive mice (ApoE-/-) which were also haploinsufficient in A20,  the A20-/-  
phenotype led to premature death due to severe inflammation in several organs (Lee et 




CD54/ICAM-1, and increased levels of NF-κB induced pro-inflammatory cytokines in 
their serum (Wolfrum et al., 2007). In a separate experiment, it was found that A20 
exerted beneficial effects at the endothelial level by suppressing CD40 activation and 
apoptosis in human coronary artery endothelial cells (Longo et al., 2003). CD40 is 
expressed on the surface of endothelial cells and CD40 ligand (CD40L) binding has been 
implicated in the pathogenesis of atherosclerosis. Diabetic, hyperglycemic mice were 
increasingly susceptible to atherosclerosis due to the glucose-triggered post-translational 
modification of the A20 protein which ultimately led to proteasome degradation of the 
protein (Shrikhande et al., 2010). Taken together, these studies suggest that the A20 
protein has a profound influence in the pathogenesis and severity of atherosclerosis. 
Some evidence suggests that probiotic organisms may down-regulate pro-
inflammatory biomarkers via increased expression of the A20 protein (O’Callaghan et 
al., 2012; O’Flaherty and Klaenhammer, 2012; Villena et al., 2012; Tomosada et al., 
2013).  This increase in A20 expression effectively down-regulates any subsequent 
expression of pro-inflammatory biomarkers at the transcriptome level by terminating the 
transcriptional activity of NF-κB. 
Peroxisome Proliferator-Activated Receptors (PPARs) 
The PPARs are a set of nuclear hormone receptors involved in the regulation of 
lipid metabolism, glucose homeostasis, and attenuation of the inflammatory response 
(Duval et al., 2002). The PPAR receptors (α, δ, γ) are activated by naturally derived fatty 
acid molecules such as conjugated linoleic acid, prostaglandins, and 9-




have anti-atherogenic properties and have been found in both human and mouse 
atherosclerotic plaques (Duval et al., 2002). Both PPARα and PPARγ down-regulate 
cytokine induced VCAM-1 expression in endothelial cells via inhibition of the NF-κB 
pathway (Marx et al., 2000; Pasceri et al., 2000). PPARγ activation has also been 
attributed with the ability to prime human peripheral blood monocytes into regulatory M2 
macrophages (Bouhlel et al., 2007). Further, it has been shown that genetic knock-outs of 
the PPARγ gene in macrophage-derived foam cells resulted in decreased cholesterol 
efflux suggesting another possible anti-atherogenic role of this receptor (Akiyama et al., 
2002; Chinetti et al., 2001). 
Some probiotics modulate the expression of pro-inflammatory cytokines through 
the increased transcription/activation of the PPARs. It is thought that some probiotic 
organisms activate the PPARs, specifically PPARγ, through the local production of 
conjugated linoleic acid (CLA). In fact, CLA produced by probiotic organisms decreased 
dextran sodium sulfate-induced colitis in a mouse model by activating PPARγ in 
macrophages (Bassaganya-Riera et al., 2012). Orally administered probiotics have also 
been shown to protect against sepsis-induced liver and colonic damage in mice through 
the activation of PPARγ (Ewaschuk et al., 2007). Further, mice which were supplied with 
capsules containing fermented milk products showed increased expression of PPARα 
mRNA in their liver (Sari et al., 2013). Collectively, these studies suggest that these 
probiotic organisms can alter systemic expression and activation of PPAR receptors and 






Chapter 1:  
Determination of the Immunomodulatory Activity of the L. rhamnosus R0011 and 
L. helveticus R0389 Secretomes on Challenged Intestinal Epithelial Cells 
Aim of Study: 
Lactobacillus rhamnosus R0011 has been shown to have immunomodulatory 
activity when cultured with IECs (Wagar et al., 2009; Foster et al., 2011; McCarville, 
2012, M. Sc. Thesis, UOIT). However, the immunomodulatory activity of Lactobacillus 
helveticus R0389 has been less characterised. Further, it is unclear whether these bacteria 
secrete bioactive molecules retaining immunomodulatory activity. The aim of this study 
was to determine the immunomodulatory activity of L. rhamnosus R0011 and L. 
helveticus R0389 secretomes on both human HT-29 and rat IEC-6 IECs stimulated with a 
wide array of pro-inflammatory stimuli. The secretome encompasses both proteins and 
other bioactive molecules secreted or shed by the cell. The transformed human HT-29 
IECs have been used as a model in vitro cell system to study the effects of bacterial 
interactions with IECs and secrete IL-8 in response to challenge from innate immune 
stimulants (Kelly et al., 1994; Abreu-Martin et al., 1995). Similarly, the primary, non-
transformed rat IEC-6 IEC cell line has been used as a model cell system to study IEC 
function in vitro (Quaroni et al., 1979). Initial characterisation of the bioactive 
constituents of both secretomes was also conducted in an attempt to elucidate potential 
mechanisms of action. Further, the ability of the L. rhamnosus R0011 secretome to 




1) Determination of the effects of  L. rhamnosus R0011 and L. helveticus R0389 on 
constitutive levels of IL-8 production by human HT-29 IEC 
 
Previous analysis has indicated that L. rhamnosus R0011 down-regulates 
constitutively produced IL-8 from human HT-29 IECs (Wallace et al., 2003). However, 
the effects of the secreted products from these Lactobacilli strains on basal IL-8 
production have not been elucidated. For this reason, HT-29 IECs were cultured with the 
L. rhamnosus R0011 and the L. helveticus R0389 secretomes to determine whether it is a 
secreted bioactive molecule from these Lactobacilli which confers the 
immunomodulatory activity. 
 
2) Determination of the effects of L. rhamnosus R0011 and L. helveticus R0389 on 
levels of IL-8 production by human HT-29 IEC challenged with a wide array of pro-
inflammatory stimuli: 
 
The ability of many strains of Lactobacilli to down-regulate pro-inflammatory 
cytokine production by human IECs challenged with innate immune stimulants has been 
characterized extensively (Thomas and Versalovic, 2010; Lebeer et al., 2008; Lebeer et 
al., 2010). However, it is unclear whether these bacteria secrete bioactive molecules 
which have anti-inflammatory activity into the extracellular environment. For this reason, 
HT-29 IECs were stimulated with a wide array of pro-inflammatory stimuli (TNF-α, IL-
1β, Poly (I:C), Flagellin, LPS). Effects of concurrent administration of either the L. 




these stimuli were examined to determine whether these Lactobacilli secrete bioactive 
molecules with the ability to down-regulate pro-inflammatory cytokine production. 
 
3) Determination of the effects of  L. rhamnosus R0011 and L. helveticus R0389 on 
constitutive levels of CINC-1 production by rat IEC-6 intestinal epithelial cells: 
 
Immunomodulatory activities of the L. rhamnosus R0011 and L. helveticus R0389 
secretomes were also tested on rat IEC-6 IECs as described previously in Objective (1). 
These cells are non-transformed, primary IECs. Changes in constitutive levels of the pro-
inflammatory chemokine, CINC-1, were measured in response to incubation with the 
secretomes. 
 
4) Determination of the effects of both Lactobacillus rhamnosus R0011 and 
Lactobacillus helveticus R0389 on levels of CINC-1 production by rat IEC-6 intestinal 
epithelial cells challenged with a wide array of pro-inflammatory stimuli: 
 
Immunomodulatory activities of the L. rhamnosus R0011 and L. helveticus R0389 
secretomes were also tested on rat IEC-6 IECs as described previously in Objective (2). 
Changes in levels of pro-inflammatory chemokine, CINC-1, were measured in response 
to concurrent incubation with the secretomes and either poly (I:C), flagellin, or LPS. 
 
5) Characterisation of the bioactive constituents of the L. rhamnosus R0011 and the 





Some probiotic microorganisms secrete small bioactive molecules retaining anti-
inflammatory activity (Ganguli et al., 2013). For this reason, size-fractionation of the two 
secretomes using a filter with a MW cutoff of 10 kDa was conducted in order to 
determine whether the secreted bioactive molecule is less than 10 kDa in size. Further 
characterization was done by neutralizing the pH of the secretome to physiological pH 
with sodium hydroxide, determining the isomer configuration of the lactic acid produced 
by both strains of Lactobacilli, and the ability of each strain to produce extracellular ATP. 
 
6) Determination of the ability of the L. rhamnosus R0011 secretome to inhibit the 
growth of Salmonella typhimurium 
 
Previous analysis has shown that Lactobacilli can antagonize the attachment of S. 
typhimurium to human IECs (Lehto and Salimen, 1997). We hypothesized that L. 
rhamnosus R0011 secretes antimicrobial compounds capable of antagonizing the growth 
of S. typhimurium. To test this hypothesis, overnight cultures of S. typhimurium were 










Analysis of the effects of L rhamnosus R0011-derived fermented milk on the 
expression of pro-atherogenic biomarkers using an in vitro cell system 
Aim of Study: 
The aim of this study was to examine the effects of L rhamnosus R0011 fermented dairy 
milk on the expression of pro-atherogenic biomarkers using in vitro cell models. 
1) Determination of the effects of L. rhamnosus R0011 fermented milk on cytokine 
expression by human THP-1 and U937 monocyte cells challenged with LPS: 
 
In an attempt to elucidate the range of bioactivity of milk fermented with L. 
rhamnosus R0011, milk ferments were tested directly on human monocyte cells using 
standard cell line models. Since there have been reports describing differences in 
cytokine profiles between cell types following challenge, milk ferments were tested on 
both human THP-1 and U937 cells.  The THP-1 cell line is a well-established model for 
studying the roles of both monocytes and macrophages in atherosclerosis (Qin, 2012; 
Chanput et al., 2014). Stimulation of THP-1 and U937 cells with LPS has been shown to 
elicit a similar cytokine expression profile as those observed in monocytes and 
macrophages in atherosclerotic lesions (Sharif et al., 2007; Huang et al., 2012). 
Therefore, monocytes were exposed to LPS and cultured with L. rhamnosus R0011 milk 
ferments or acidified and unfermented milk controls. Further, cells were pre-treated with 




plays an integral role on any observed immunomodulatory activity of the milk ferments. 
Changes in both pro-inflammatory and regulatory cytokines were measured. 
2) Determination of the effects of Lactobacillus rhamnosus R0011 fermented milk 
on cytokine and cell surface molecule expression by THP-1 and U937 derived resting 
macrophages challenged with lipopolysaccharide: 
 
Since macrophages play an integral role in the pathogenesis of atherosclerosis, 
milk ferments prepared with L. rhamnosus R0011 were tested on both U937- and THP-1-
derived macrophages. Changes in cytokine profiles in response to challenge with LPS 
and L. rhamnosus R0011 ferments were measured. As macrophages exist in a 
heterogeneous population in atherosclerotic plaques and produce specific cytokine 
profiles, the ferments were tested for the ability to transform M0 resting macrophages 
into the regulatory/anti-inflammatory M2 macrophage. Further, the ability of the milk 












Materials and Methods 
Cell Culture 
The HT-29 human colorectal adenocarcinoma cell line was obtained from the 
American Type Culture Collection (ATTC) (ATCC #HTB-38) and was maintained in 
RPMI-1640 medium supplemented with 10% fetal bovine serum (FBS) and 0.05 mg/mL 
gentamicin (Sigma-Aldrich, MO, USA) and were grown in 75cm2 tissue culture flasks 
(Greiner-Bio-One, NC, USA) at 37oC, 5% CO2 in a humidified incubator (Thermo 
Fisher, MA, USA). Cells were passaged every three days or when cells reached 
approximately 90% confluency. To passage, HT-29 cell culture medium was aspirated 
and replaced with 4 mL of 20% trypsin-EDTA (Sigma-Aldrich, MO, USA); flasks were 
then incubated at 370C for 5 minutes to detach cells from the tissue culture flask. Trypsin 
was neutralized by the addition of 8 mL of HT-29 cell culture medium (containing FBS) 
to the flask. Cells were then collected by centrifugation at 300 x g for 10 minutes. 
Following centrifugation, the supernatant was removed and the HT-29 IEC were 
resuspended in 4 mL of HT-29 cell culture medium. A 1 in 10 dilution was performed of 
the resuspended cell culture with HT-29 cell culture medium into the tissue culture flask. 
The non-transformed rat IEC-6 (ATCC #CRL-1592) small intestinal cell line was 
maintained in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma-Aldrich, MO, 
USA) supplemented with 10% FBS and 0.05mg/mL gentamicin, and cell cultures were 
maintained in a similar manner to HT-29 cells. 
The THP-1 human peripheral blood monocyte cell line (ATCC #TIB-202) was 




with 0.05 mM β-mercaptoethanol, 10% FBS and 0.05 mg/mL gentamicin in a humidified 
incubator at 37oC and 5% CO2. THP-1 cells were sub-cultured every 4-5 days by 
centrifuging cells at 300 x g for 10 minutes. Supernatants were aspirated and cells were 
resuspended with 4 mL of THP-1 cell culture medium and a 1 in 10 dilution of the 
resuspended cell culture was performed with THP-1 cell culture medium into the tissue 
culture flask. 
The U937 human myeloid monocyte cell line (ATCC #CRL-1593.2) was 
obtained from the ATCC. Cells were maintained in RPMI-1640 supplemented with 10% 
FBS, 1 mM sodium pyruvate, 2 mM L-glutamate and 0.05 mg/mL of gentamicin. Cells 
were maintained similarly to the THP-1 cells. 
Preparation of the L. rhamnosus R0011 and L. helveticus R0389 secretomes 
 Lactobacillus rhamnosus R0011 was obtained from Lallemand Health Solutions 
Inc. (Montreal, Quebec, Canada).   Starting from a lyophilized stock, bacteria were 
weighed aseptically and washed 3X in sterile phosphate-buffered saline (PBS). Between 
each wash step, bacteria were centrifuged at 3000 x g for 20 minutes at 4oC. Following 
washes, the bacteria were diluted 1 in 50 in deMan, Rogosa and Sharpe (MRS) medium 
(Difco, Canada) and placed in a shaking incubator at 37oC and 200-220 rpm for 17 hours 
or until an OD620 = 1.64 was reached.  This had previously been determined to indicate 
stationary phase for these bacteria. The bacterial culture was then diluted 1 in 5 in either 
non-supplemented RPMI-1640 or DMEM medium and allowed to further propagate for 
an additional 23 hours under the same conditions. A control consisting of MRS only, or 




culture. Following incubation, the pH of the L. rhamnosus R0011 culture was measured 
and the pH of the control was adjusted to that of the bacterial culture using concentrated 
HCl. Both the bacterial culture and the control were then centrifuged at 3000 x g for 20 
minutes and filtered through a 0.22 µm filter (Progene, Canada) to remove any bacteria 
and stored at -80oC. For some experiments, the filtered secretome samples were also 
subjected to size fractionation using a <10 kDa Amicon Ultra – 15 centrifugal filter 
(EMD Millipore, MA, USA). The less than 10 kDa fraction of the secretome was also 
stored at -80oC. A portion of the filtered secretome was plated on MRS agar to ensure 
that all bacteria had been removed. 
 Lactobacillus helveticus R0389 was obtained from Lallemand Health Solutions 
Inc. (Montreal, Quebec). Starting from a frozen stock, bacteria were diluted 1 in 50 in 
fresh MRS medium and subjected to the same incubation periods as those described for 
production of the L. rhamnosus R0011 secretome. Following incubation, cultures were 
also filtered through a 0.22 µm filter and a portion of the secretome was also subjected to 
centrifugal filtration through a <10 kDa filter. Aliquots of the secretome and the less than 








 IEC challenge with innate immune stimulants and L. rhamnosus R0011 and L. 
helveticus R0389 secretomes 
For cell challenges, HT-29 and IEC-6 IEC were enumerated and viability 
determined using Trypan Blue following sub-culturing. Cells were then resuspended in 
complete culture medium and seeded at a concentration of 5 x 105 cells/mL in 96-well 
tissue culture treated plates. Plates were then placed in the CO2 incubator for 48 hours or 
until cells formed a complete monolayer. Cells were then exposed to varied innate 
immune stimulants and dilutions of the L. rhamnosus R0011 or the L. helveticus R0389 
secretome or acidified controls concurrently for 6 hours at 37oC and 5% CO2 in a 
humidified incubator. Innate immune stimulants included human IL-1β (Cedarlane, ON, 
Canada), human TNF-α (PeproTech, QC, Canada), poly (I:C) (Sigma-Aldrich, MO, 
USA), flagellin isolated from Salmonella typhimurium (Enzo Life Sciences, ON, 
Canada), and LPS isolated from Escherichia coli K12 (InvivoGen). For some cell 
challenges, cells were cultured with an A2A receptor antagonist (Sigma-Aldrich, MO, 
USA), a CD73 blocker (Adenosine 5′-(α,β-methylene)diphosphate) (Sigma-Aldrich, MO, 
USA), a PPARγ antagonist (GW9662) (Sigma-Aldrich, MO, USA), or pH neutralised 
(pH=7.4) L. rhamnosus secretome. Following IEC challenge, supernatants were collected 
and stored at -80oC for cytokine quantification and IEC viabilities were determined. All 
cell challenges were done using FBS-free RPMI-1640 medium for HT-29 IECs or non-
supplemented DMEM medium for IEC-6 IECs (with the exception of LPS challenge, 





Table 2. Innate immune stimulants used to incite pro-inflammatory cytokine production 
by HT-29 and IEC-6 IECs 
Innate Immune Stimulant Concentration Receptor 
Lipopolysaccharide (LPS) 20 ng/mL TLR-4 
Poly (I:C) 40 µg/mL TLR-3 
Human Tumor Necrosis 
Factor – α (TNF-α) 
50 ng/mL TNF-
Receptor 
Flagellin 100 ng/mL TLR-5 
Human Interleukin-1β (IL-1β) 30 ng/mL IL-1 
Receptor 
 
Salmonella typhimurium growth inhibition assay 
 Overnight cultures of Salmonella typhimurium were grown in tryptone soya broth 
(TSB) (Oxoid) prior to use. S. typhimurium was incubated with 40% v/v of the L. 
rhamnosus R0011 secretome and either an HCl acidified control or L (+) lactic acid 
control to account for any effect of pH or lactic acid on the growth of S. typhimurium, for 
6 hours at 37oC under agitation. The OD600 of the cultures were determined every hour 
for a total of 6 reads. Serial dilutions of S. typhimurium were plated on TSB agar after 
each read to enumerate the bacteria to determine the viability of the bacteria following 
the different treatments. 
Preparation of the L. rhamnosus R0011 milk ferment 
3.25% milk was inoculated with 1x108 CFU/mL of L. rhamnosus R0011, placed 




obtained. A non-fermented milk control and a lactic acid acidified milk control were also 
subjected to the same incubation period under the same conditions. A portion of the L. 
rhamnosus R0011 ferment was subjected to filtration through 5.0 µm, 1.2 µm, and 0.2 
µm to remove the bacteria to determine whether or not any observed immunomodulatory 
activity could be attributed to fermentation products of the bacteria. The lactic acid 
acidified milk control was prepared by determining the concentration of lactic acid in the 
L. rhamnosus R0011 ferment and adding the determined amount of lactic acid to the 
acidified control. If further reduction in pH was necessary following the addition of the 
correct concentration of lactic acid, HCl was added to reduce the pH of the acidified 
control to that of the L. rhamnosus R0011 ferment. L. rhamnosus R0011 was enumerated 
following fermentation by plating serial dilutions on MRS agar plates. Ferments, filtered 
ferments, non-fermented and acidified milk controls were immediately frozen in 1mL 
aliquots at -80oC.  
Determination of the concentration of lactic acid in the L. rhamnosus R0011 ferment 
and secretome 
The lactic acid concentration in the L. rhamnosus R0011 milk ferment and 
secretome was determined by using the commercially available Lactic Acid 
Determination Kit from Megazyme (Wicklow, Ireland). This kit also allows for the 
determination of the isoform configuration of the lactic acid present within the sample. 
Briefly, D-LDH and L-LDH were added to the fermented milk/secretome samples in the 
presence of NAD+ and D-glutamate-pyruvate transaminase (D-GPT). The amount of 




the amount of D(-)/L(+)-lactic acid present. Following incubation, the absorbance (nm) 
of the samples was measured and compared to the lactic acid standard. 
Determination of ATP concentration in the L. rhamnosus R0011 ferment and 
secretome 
 ATP concentrations in the L. rhamnosus R0011 milk ferment and the L. 
rhamnosus R0011 and L. helveticus R0389 secretomes were determined using the 
commercially available ATP Determination Kit from Molecular Probes (Invitrogen, ON, 
Canada). D-luciferin, firefly luciferase, and dithiothreitol were added to samples in black 
96-well plates (Greiner Bio-One, NC, USA). Luminescence was measured using a 
Synergy HTTR microplate reader (Bio-Tek, VT, USA). Total ATP concentration within 
the samples was determined by developing a standard curve and using the equation of the 
line of best fit. 
Determination of indole production by L. rhamnosus R0011 and L. helveticus R0389 
 The indole spot-test was used to determine whether L. rhamnosus R0011 or L. 
helveticus R0389 produce indoles in culture (Vracko and Sherris, 1963). Briefly, a few 
drops of the indole spot-test reagent (Pro-Lab Diagnostics, ON, Canada) were placed 
onto Whatman filter paper. Pure cultures of each Lactobacillus species were smeared 
onto the spots and allowed to incubate for three minutes. If indoles are present, the 4-
(Dimethylamino) cinnamaldehyde within the indole spot-test reagent will turn blue. 





Differentiation of THP-1 human peripheral blood monocyte cells into M0 
macrophages 
 Differentiation of THP-1 monocyte cells into resting M0 macrophages was 
conducted as previously performed by Chanput et al. (2014). THP-1 cells were seeded in 
12-well tissue culture treated plates (Greiner Bio-One, NC, USA) at a concentration of 1 
x 106 cells/mL. These cells were treated with 100 ng/mL of phorbol-12-myristate-13-
acetate (PMA) for 48 hours at 37oC, 5% CO2 in a humidified incubator. Following this 
incubation, the culture medium containing PMA was removed and cells were washed 2X 
with complete THP-1 medium and allowed to rest in complete medium for an additional 
24 hours prior to  challenge with a pro-inflammatory stimulus. Differentiation was 
confirmed by immunophenotyping for increased expression of the macrophage cell 
surface marker CD11b. 
Differentiation of U937 human myeloid monocyte cells into M0 macrophages 
 U937 cells were seeded at a concentration of 1 x 106 cells/mL in 12-well tissue 
culture treated plates in non-supplemented RPMI-1640 medium. These cells were 
stimulated with 1 µM all-trans retinoic acid (ATRA) for 24 hours at 37oC, 5% CO2 in a 
humidified incubator, as this has previously been shown to induce U937 differentiation to 
the monocyte stage (Masotti, M. Sc. Thesis, UOIT, 2010; Zhang et al., 2008). Medium 
containing ATRA was aspirated following incubation prior to cell challenge. 
Differentiation was confirmed by immunophenotyping for increased expression of the 




THP-1 and U937 cell challenge with lipopolysaccharide and Lactobacillus 
rhamnosus R0011 milk ferments 
 U937 and THP-1 monocyte cells were seeded at a concentration of 1 x 106 
cells/mL in a 96-well tissue culture treated plate and challenged at a final concentration 
of 5 x 105 cells/mL in RPMI-1640 medium supplemented with 10% FBS. Cells were 
either pre-incubated with the L. rhamnosus R0011 milk ferments (either whole or 
filtered) or lactic acid acidified controls (either whole or filtered) or an unfermented milk 
control for 18 hours prior to challenge with 125 ng/mL of LPS for 6 hours or cultured 
with L. rhamnosus R0011 ferments or controls with LPS concurrently for 24 hours. 
Following challenge, cells were collected or removed by centrifugation at 300 x g for 10 
minutes and supernatants were collected and stored at -80oC for cytokine analysis. Initial 
characterisation of the effects of the L. rhamnosus R0011 milk ferment/controls was 
conducted by testing a series of dilutions (1/10, 1/50, 1/100, 1/1000) of the ferments and 
acidified or non-acidified controls on the cells. All subsequent challenges only examined 
the effects of the 1/50 ferment dilution (and pH-matched controls) as this concentration 
was shown to modulate the immune response without having a negative impact on cell 
viability.  
 Differentiated U937 and THP-1 M0 macrophages were challenged in a similar 
manner as the U937 and THP-1 monocyte cells. M0 macrophages were either pre-
incubated with L. rhamnosus R0011 ferments or controls for 18 hours prior to challenge 
with 125 ng/mL LPS or cultured with L. rhamnosus R0011 ferments or controls 




10 minutes prior to supernatant collection, and supernatants were immediately frozen at -
800C until analyzed for cytokine concentrations. 
Cytokine Quantification 
 Human IL-1β (R&D Systems, Catalogue #DY201), IL-6 (R&D Systems, 
Catalogue #DY206), IL-1Ra (R&D Systems, Catalogue #DY280), IL-8 (R&D Systems, 
Catalogue #DY208), TNF-α (R&D Systems, Catalogue #DY210), TGF-β (R&D 
Systems, Catalogue #DY208), and rat CINC-1 (R&D Systems, Catalogue # DY515) were 
quantified from cell culture supernatants using enzyme-linked immunosorbant assays 
(ELISA) following manufacturer’s protocols (R&D Systems, MN, USA). IL-10 
(BioLegend, Catalogue #430603) and IL-12(p70) (BioLegend, Catalogue #431702) were 
also quantified from cell culture supernatants following manufacturer’s protocols 
(BioLegend, CA, USA). All ELISAs were done using 96-well high-binding Microlon 600 
ELISA plates (Greiner Bio-One, NC, USA). Plates were coated with capture antibody (at 
the concentration indicated by the manufacturer) and incubated at 4oC overnight. 
Following sample loading and the addition of biotinylated detection antibody, 
horseradish peroxidase-conjugated streptavidin and its substrate, 3,3′,5,5′-
tetramethylbenzidine (TMB) (Sigma-Aldrich, MO, USA), were added. The reaction was 
stopped with 1.8 N H2SO4 and plates were read at a wavelength of 450nm using a 
Synergy HTTR microplate reader (Bio-Tek Instrumentation, VT, USA).  
Determination of cell surface molecule expression 
 Cell surface molecule expression was quantified using the Millipore Guava 




challenge, HT-29 IEC or differentiated U937 and THP-1 macrophages were dislodged 
from the tissue culture plates using a cell scraper, and collected by centrifugation at 300 x 
g for 10 minutes. Cells were counted (and viability determined) using the Trypan Blue 
exclusion assay and resuspended at a concentration of 1 x 106 cells/mL in 100 µL of 
Double Protein Staining Buffer (5% FBS, 5% BSA in PBS, pH 7.4). Cells were stained 
with phycoerythrin (PE) conjugated antibodies and their corresponding isotype controls 
for 30 minutes on ice in the dark. Antibodies used were human anti-CD54 (Clone 
HCD54) (BioLegend, CA, USA), human anti-CD11b (Clone ICRF44) (BioLegend, CA, 
USA), human anti-CD73 (Clone (BioLegend, CA, USA), and isotype controls were 
IgG1, κ (Clone MOPC-21) (BioLegend, CA, USA) and IgG2a, κ (Clone MOPC-173) 
(BioLegend, CA, USA). Following incubation, cells were washed two times in 1mL of 
Double Protein Staining Buffer. Between each wash step, cells were centrifuged at 300 x 
g for 5 minutes at 4oC and supernatants were aspirated. After the final wash, cells were 
resuspended in 500 µL of sterile, ice-cold PBS and incubated on ice, in the dark, for 5 
minutes. Data were collected using the Guava Express Software and exported to 
Microsoft Excel. All data were reported as mean fluorescence intensity (MFI). FCS 
Express Flow Cytometry Software was used for generation of histograms and the 
Overton subtraction to determine percentage positive CD11b and CD73 expression.  
Determination of cell viability following cell challenges 
Cell viability was measured to ensure that any change in cytokine production was 
not due to cell death. Both the XTT cell viability assay (Roehm et al., 1991) and Trypan 
Blue exclusion assay were used to determine cell viability of both U937 and THP-1 cells 




did not receive the whole ferment as bacteria also yield a positive result when incubated 
with the XTT reagent. If cells were alive, a soluble formazan product would be produced. 
Following incubation for 2 hours at 37oC, the absorbance was measured at 450 nm and a 
background wavelength of 650 nm was subtracted. The Trypan Blue exclusion assay was 
used to determine the viability of those cells exposed to the whole ferment. All treatments 
were compared to the negative control (those cells which only received cell culture 
medium) and the % viability, relative to the negative control, was determined. 
For determination of IEC viability following challenge, the MTT cell viability 
assay was used (Mosman, 1983). Briefly, the MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
Diphenyltetrazolium Bromide) reagent (Sigma-Aldrich, MO, USA) was diluted to 0.5 
mg/mL in either non-supplemented RPMI-1640 or DMEM medium. Cell culture 
supernatants were removed and replaced with the diluted MTT reagent. If cells were 
actively respiring, cells would produce an insoluble formazan product. Following 
incubation for 3 hours at 37oC, formazan crystals were dissolved using dimethyl 
sulfoxide and the absorbance was then measured at 600 nm. All treatments were 
compared to the negative control (those cells which only received cell culture medium) 
and the % viability, relative to the negative control, was determined. 
Statistical Analysis 
Statistical analysis was done using GraphPad Prism’s one-way analysis of 
variance (ANOVA) and further analysis was done using Tukey’s multiple comparison 
test when the ANOVA indicated significant differences were present. For some analyses, 




shown as the mean ± standard error of the mean (SEM) where one biological replicate 



























Effects of the L. rhamnosus R0011 and L. helveticus R0389 Secretomes on 
Challenged IEC and Characterisation of the Bioactive Constituents of the 
Secretomes 
The L. rhamnosus R0011 and L. helveticus R0389 secretomes do not down-regulate 
constitutive IL-8 production from human HT-29 IEC 
 In order to elucidate whether the L. rhamnosus R0011 or the L. helveticus R0389 
secretomes could down-regulate constitutive IL-8 production from HT-29 cells, cells 
were cultured with either secretome for six hours and levels of IL-8 were measured. 
Neither the L. rhamnosus R0011 nor the L. helveticus R0389 secretomes down-regulated 
constitutive IL-8 production from HT-29 IEC (Figures 1 and 2).  
The L. rhamnosus R0011 and L. helveticus R0389 secretomes down-regulate IL-8 
production from challenged human HT-29 IEC 
To determine whether or not the L. rhamnosus R0011 or the L. helveticus R0389 
secretomes could down-regulate IL-8 production from challenged HT-29 IEC, cells were 
cultured with either the L. rhamnosus R0011 or the L. helveticus secretome and an innate 
immune stimulant for six hours and changes in IL-8 production were measured. Both 
secretomes significantly down-regulated IL-1β-induced IL-8 production (Figures 3 and 
4), poly (I:C)-induced IL-8 production (Figures 5 and 6), LPS-induced IL-8 production 
(Figures 8 and 9), and TNF-α-induced IL-8 production (Figures 10 and 11) from HT-29 
IECs. Further, the L. rhamnosus R0011 secretome was able to down-regulate flagellin-




both the L. rhamnosus R0011 and the L. helveticus R0389 secretomes significantly down-
regulated IL-8 production from activated HT-29 IEC as well (Figures 3-11).    
The L. rhamnosus R0011 and L. helveticus R0389 secretomes do not down-regulate 
constitutive CINC-1 production from rat IEC-6 intestinal epithelial cells 
Rat IEC-6 cells were cultured with either the L. rhamnosus R0011 or the L. 
helveticus R0389 secretomes for six hours and changes in production of the pro-
inflammatory chemokine CINC-1 were measured. It was determined that neither 
secretomes significantly down-regulated constitutive CINC-1 production from IEC-6 
cells (Figures 12 and 13). 
The L. rhamnosus R0011 and L. helveticus R0389 secretomes have differential 
effects on CINC-1 production from challenged rat IEC-6 cells 
 To determine whether the two secretomes could down-regulate pro-inflammatory 
cytokines secreted by challenged IEC-6 cells, cells were cultured with different innate 
immune stimulants and either the L. rhamnosus R0011 or the L. helveticus R0389 
secretomes for six hours and changes in CINC-1 were measured. The L. rhamnosus 
R0011 secretome did not down-regulate poly (I:C)-induced CINC-1 production from 
IEC-6 cells (Figure 14), indicating a difference from the observed effects on poly(I:C)-
induced IL-8 production by HT-29 IEC. In contrast, the L. rhamnosus R0011 secretome 
did down-regulate flagellin-induced CINC-1 production and LPS-induced CINC-1 
production from IEC-6 cells. This down-regulation was also observed in IEC-6 cells 
cultured with the less than 10 kDa fraction of the secretome (Figures 16 and 18). 




CINC-1 production, flagellin-induced CINC-1 production, or LPS-induced CINC-1 
production by IEC-6 cells. The same trend was also observed when cells were cultured 
with the less than 10 kDa fraction of the R0389 secretome (Figures 15, 17, and 19). 
Characterisation of the bioactive constituents of the L. rhamnosus R0011 and L. 
helveticus R0389 secretomes 
 Initial characterisations of secreted products within the L. rhamnosus R0011 and 
the L. helveticus R0389 secretomes were conducted in an attempt to identify any 
bioactive constituents. It was found that L. rhamnosus R0011 predominately secretes 
L(+)-lactic acid while the L. helveticus R0389 predominately secretes D(-)-lactic acid 
(Figure 20). Further, it was determined that both the L. rhamnosus R0011 and the L. 
helveticus R0389 secretomes contain ATP, with some degree of difference in the ATP 
levels between strains (Figure 21). Finally, the ability of these two strains of Lactobacilli 
to produce indoles was determined. Both strains tested negative for indole production 
(Table 4). 
The L. rhamnosus R0011 secretome did not modulate the expression of the AMP 
converting enzyme CD73 (Ecto-5’-Nucleotidase) by HT-29 IEC 
 HT-29 IEC express CD73 on the cell surface (Figures 22 and 23). To determine 
whether or not the L. rhamnosus R0011 secretome could modulate the expression of this 
adenosine generating enzyme, HT-29 IECs were cultured with the less than 10 kDa 
fraction of the secretome.  Effects on CD73 expression were also measured following 
addition of TNF-α (50ng/mL). There was no significant difference in the expression of 




of the other treatment groups, and TNF-α did not induce increased CD73 expression 
(Figure 24). Further, blocking of the CD73 enzyme with Adenosine 5′-(α,β-methylene) 
diphosphate  (50µM; Schenck et al., 2013) did not  appear to reverse the down-regulation 
of IL-8 production by HT-29 IEC cultured with TNF-α and the L. rhamnosus R0011 
secretome (Figure 25). 
The L. rhamnosus R0011 Secretome did not act through the A2A Adenosine 
Receptor  
 To determine whether or not the L. rhamnosus R0011 secretome 
immunomodulatory activity is mediated by the A2A adenosine receptor, HT-29 IECs 
were cultured with the selective A2A adenosine receptor antagonist 4-(2-[7-Amino-2-(2-
furyl)[1,2,4]triazolo[2,3-a][1,3,5]triazin-5-ylamino]ethyl)phenol (ZM241385; 500nM) 
(Schenck et al., 2013), the less than 10 kDa fraction of the secretome, and changes in 
TNF-α-induced IL-8 production were measured. The addition of the A2A adenosine 
receptor antagonist did not appear to reverse the down-regulation of TNF-α-induced IL-8 
production by HT-29 IEC cultured with the L. rhamnosus R0011 secretome (Figure 26).  
Down-regulation of IL-8 production by the L. rhamnosus R0011 Secretome was not 
mediated through PPARγ 
 HT-29 IECs were cultured with the L. rhamnosus R0011 secretome, TNF-α, and 
GW9662, a selective PPARγ antagonist (5 µM; Lea et al., 2004; Leesnitzer et al., 2002) 
and changes in TNF-α-induced IL-8 production were measured. The PPARγ antagonist 
was unable to the reverse the ability of the R0011 secretome to down-regulate TNF-α-




Neutralising the pH of the L. rhamnosus R0011 secretome reverses the effect on IL-8 
production  
 The pH of the L. rhamnosus R0011 secretome was neutralised to physiological 
pH (pH = 7.4) by the addition of sodium hydroxide, in order to determine whether the 
bioactivity of the secretome was pH-dependant. Neutralised L. rhamnosus R0011 or the 
less than 10 kDa fraction of the R0011 secretome did not significantly reduce TNF-α-
induced IL-8 production from HT-29 IEC (P > 0.05) (Figure 28).  
The L. rhamnosus R0011 secretome inhibits the growth of S. typhimurium 
 Overnight cultures of S. typhimurium were cultured with the L. rhamnosus R0011 
secretome, the less than 10 kDa fraction of the R0011 secretome, or acidified controls, 
over a six hour period.  L. rhamnosus R0011 and its less than 10 kDa secretome fraction 
significantly inhibited the growth of S. typhimurium. This growth inhibitory effect was 










Effects of L. rhamnosus R0011-derived Fermented Milk on the Expression of Pro-
atherogenic Biomarkers by U937 and THP-1 cells 
Characterisation of the L. rhamnosus R0011 milk ferments 
 Fermentation kinetics of L. rhamnosus R0011 grown in 3.25% milk were 
determined using different inoculum sizes. Growth was monitored over time and changes 
in pH were measured. It was determined that a starting inoculum of 1 x 108 CFU/mL 
yielded optimal fermentation kinetics (Figure 30). Further it was determined that L. 
rhamnosus R0011 primarily produces L(+)-lactic acid (Figure 31) and secretes ATP into 
the fermented milk product (Figure 32), although ATP levels were lower than those 
observed in the R0011 secretome (Figure 21). 
Pre-incubating U937 or THP-1 human monocyte cells with L. rhamnosus R0011-
derived fermented milk prior to LPS challenge has differential effects on cytokine 
production 
 U937 human monocyte cells were pre-incubated with L. rhamnosus R0011-
derived milk ferments followed by LPS challenge and changes in production of IL-8, 
sCD54, and IL-1Ra were measured. Levels of IL-8 production increased in those cells 
pre-incubated with the filtered L. rhamnosus R0011 milk ferments and the unfermented 
milk control (Figure 33). In contrast, there were no changes in sCD54 (Figure 34) or IL-
1Ra production (Figure 35) between LPS-challenged cells and those cells pre-incubated 




 In contrast, pre-incubating THP-1 human monocyte cells with L. rhamnosus 
R0011-derived milk ferments followed by LPS challenge had no effect on IL-8 (Figure 
39), sCD54 (Figure 40) or IL-1Ra production (Figure 41). 
Culturing U937 or THP-1 human monocyte cells with L. rhamnosus R0011-derived 
fermented milk and LPS has differential effects on cytokine production 
 U937 human monocyte cells were cultured with the L. rhamnosus R0011-derived 
milk ferments and modulation of IL-8, sCD54, and IL-1Ra was determined. There was no 
change in IL-1Ra (Figure 38) or IL-8 (Figure 36) production between LPS-challenged 
cells and those cells cultured with LPS and the L. rhamnosus R0011-derived milk 
ferments or milk controls. However, there was a significant down-regulation of sCD54 in 
those cells cultured with the whole L. rhamnosus R0011 milk ferment. This down-
regulation was also observed for U937 monocyte cells cultured with the lactic acid and 
non-fermented milk controls (Figure 37), suggesting an effect of a component of milk not 
associated with fermentation or acidification. 
 In contrast, THP-1 human monocyte cells which were cultured in media 
containing the L. rhamnosus R0011-derived milk ferments or milk controls showed no 
changes in LPS-induced IL-8 (Figure 42), sCD54 (Figure 43), or IL-1Ra production 
(Figure 44). 
Culturing U937 or THP-1-derived macrophages with L. rhamnosus R0011-derived 
fermented milk and LPS has differential effects on cytokine production 
 U937 human monocytes were differentiated into macrophages using ATRA and 




(Figure 45 and 46). U937-derived resting macrophages were cultured with the L. 
rhamnosus R0011-derived milk ferments and LPS and changes in IL-10, IL-1Ra, sCD54, 
total TGF-β, IL-8, IL-6, and IL-1β were measured. There was a significant increase in 
LPS-induced IL-10 production by those cells cultured with the L. rhamnosus R0011 
whole milk ferment (Figure 47) relative to LPS-challenged cells cultured with the whole 
lactic acid control or the unfermented milk control. There was also a significant increase 
in LPS-induced IL-1Ra production by cells cultured with both the whole and filtered L. 
rhamnosus R0011 milk ferments relative to the negative control (Figure 48). Finally, 
there was a significant increase in LPS-induced IL-6 production by cells cultured with the 
whole L. rhamnosus R0011 ferment. This increase in LPS-induced IL-6 production was 
not observed for cells incubated with the lactic acid or non-fermented milk controls 
(Figure 52). In contrast, there was no modulation of sCD54 production (Figure 49), total 
TGF-β production (Figure 50), IL-8 production (Figure 51), IL-1β production (Figure 
53), IL-12p70 production or TNF-α production (Table 5) between cells challenged with 
LPS or those cultured with L. rhamnosus R0011-derived milk ferments or controls and 
LPS. 
 THP-1 human monocytes were differentiated into macrophages using PMA and 
differentiation was confirmed by immunophenotyping for increased expression of CD11b 
(Figure 55 and 56). THP-1 resting macrophages were cultured with LPS and the L. 
rhamnosus R0011-derived milk ferments or milk controls and changes in IL-10, IL-1Ra, 
sCD54, total TGF-β, IL-8, IL-6, and IL-1β were measured. IL-10 production was 
significantly increased in those cells cultured with LPS and the L. rhamnosus R0011 




(Figure 57). There was also a significant increase in IL-1β production from cells cultured 
with LPS and the L. rhamnosus R0011 whole milk ferment. This increase was not 
observed in cells cultured with the acidified or non-fermented milk controls (Figure 63). 
In contrast, there was no change in LPS-induced IL-1Ra production (Figure 59), IL-8 
production (Figure 60), IL-6 production (Figure 62), total TGF-β production (Figure 64), 
IL-12p70 (Table 5) production or TNF-α production (Figure 61). 
L. rhamnosus R0011 milk ferments do not decrease LPS-induced CD54 expression 
on U937 and THP-1 resting macrophages 
 Both U937 and THP-1 resting macrophages were cultured with LPS and L. 
rhamnosus R0011-derived milk ferments or milk controls and changes in the surface 
expression of CD54/ICAM-1 was measured. LPS significantly increased the expression 
of CD54/ICAM-1 in both U937 and THP-1 macrophages (Figures 54 and 65). However, 
neither the L. rhamnosus R0011-derived milk ferments nor the milk controls were found 
to modulate the expression of LPS-induced CD54/ICAM-1 expression on U937 (Figure 








Table 3. Cytokines and chemokines involved in the pathogenesis of atherosclerosis. 
Cytokine
1 




Myriad of cells 
including smooth 





Tedgui and Mallat, 
2006; Girn et al., 2007 
IL-6 Macrophages, T cells, 
Endothelial cells 
T cells, B cells, 
Endothelial cells, 
Smooth muscle cells  
• Pro-atherogenic 
• Differentiation agent of monocytes 
• Increases CD54/ICAM-1 expression 
Tedgui and Mallat, 
2006 
IL-10 Monocytes, 
Macrophages (M2),  
Macrophages, T cells, 
B cells 
• Anti-atherogenic 
• Inhibits the production of       
proinflammatory cytokines 
Girn et al., 2007; 
Tedgui and Mallat, 
2006 
TGF-β1 Macrophages, 
Monocytes, T cells 
Myriad of cell types • Anti-atherogenic Tedgui and Mallat, 
2006 
TNF-α Monocytes, 
Macrophages, ECs, T 
cells 
Cells including 
smooth muscle cells 
and endothelial cells 
• Pro-inflammatory 
• Pro-atherogenic 
• Activates endothelial cells 







• Antagonizes the effect of IL-1β 
Girn et al., 2007 
Chemokines     




Neutrophils and T 
cells 
• Pro-atherogenic 
• Potent chemoattractant of neutrophils 
and T cells 
Tedgui and Mallat, 
2006 




Table 4. Preliminary characterisation of the bioactive constituents found within the L. 
rhamnosus R0011 and the L. helveticus R0389 secretomes 
L. rhamnosus R0111 L. helveticus R0389 
L-lactic acid D-lactic acid 
High levels of ATP Low levels of ATP 
Indole negative Indole negative 















Table 5. Immunomodulatory activity of the L. rhamnosus R0011 milk ferments on LPS-
challenged U937 and THP-1-derived macrophages. 
Cytokine/Chemokine 
Modulation by L. 
rhamnosus R0011 Milk 
Ferment on LPS-challenged 
THP-1 Macrophages 
Modulation by L. 
rhamnosus R0011 Milk 
Ferment on LPS-challenged 
U937 Macrophages 
IL-1Ra No Change1 Increase 
IL-10 Increase Increase 
IL-1β Increase No Change 
TNF-α No Change2 No Change 
IL-12p70 No Change2 No Change2 
IL-6 No Change Increase 
TGF-β No Change No Change 
IL-8 No Change No Change 
sCD54 No Change No Change 
1There were no statistically significant differences between LPS-challenged cells and 
those cells cultured with the L. rhamnosus R0011-derived milk ferments and LPS 















































































Figure 1. HT-29 IEC cultured with 40% v/v R0011 secretome (whole or <10 kDa 
fraction) or an HCl acidified control concurrently for 6 hours (n=6). Data shown are the 
mean IL-8 production ± SEM.  Statistical analysis was performed using one-way 








Figure 2. HT-29 IEC cultured with 40% v/v R0389 secretome (whole or <10 kDa 
fraction) or an HCl acidified control concurrently for 6 hours (n=4). Data shown are the 
mean IL-8 production ± SEM.  Statistical analysis was performed using one-way 









Figure 3. HT-29 IEC stimulated with IL-1β and cultured with 40% v/v R0011 secretome 
(whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 hours (n=6). 
Data shown are the mean IL-8 production ± SEM.  Statistical analysis was performed 
using one-way ANOVA (P<0.001). Different letters denote significant differences 







Figure 4. HT-29 IEC stimulated with IL-1β and cultured with 40% v/v R0389 secretome 
(whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 hours (n=4). 
Data shown are the mean IL-8 production ± SEM.  Statistical analysis was performed 
using one-way ANOVA (P<0.001). Different letters denote significant differences 



















































































Figure 5. HT-29 IEC stimulated with Poly(I:C) and cultured with 40% v/v R0011 
secretome (whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 
hours (n=6). Data shown are the mean IL-8 production ± SEM.  Statistical analysis was 
performed using one-way ANOVA (P<0.001). Different letters denote significant 































































Figure 6. HT-29 IEC stimulated with Poly(I:C) and cultured with 40% v/v R0389 
secretome (whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 
hours (n=4). Data shown are the mean IL-8 production ± SEM.  Statistical analysis was 
performed using one-way ANOVA (P<0.001). Different letters denote significant 







Figure 7. HT-29 IEC stimulated with Flagellin and cultured with 40% v/v R0011 
secretome (whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 
hours (n=6). Data shown are the mean IL-8 production ± SEM.  Statistical analysis was 
performed using one-way ANOVA (P<0.001). Different letters denote significant 

































































Figure 8. HT-29 IEC stimulated with LPS and cultured with 40% v/v R0011 secretome 
(whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 hours (n=6). 
Data shown are the mean IL-8 production ± SEM.  Statistical analysis was performed 
using one-way ANOVA (P<0.001). Different letters denote significant differences 








Figure 9. HT-29 IEC stimulated with LPS and cultured with 40% v/v R0389 secretome 
(whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 hours (n=4). 
Data shown are the mean IL-8 production ± SEM.  Statistical analysis was performed 
using one-way ANOVA (P<0.001). Different letters denote significant differences 



























































Figure 10. HT-29 IEC stimulated TNF-α and cultured with 40% v/v R0011 secretome 
(whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 hours (n=6). 
Data shown are the mean IL-8 production ± SEM.  Statistical analysis was performed 
using one-way ANOVA (P<0.001). Different letters denote significant differences 









Figure 11. HT-29 IEC stimulated TNF-α and cultured with 40% v/v R0389 secretome 
(whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 hours (n=4). 
Data shown are the mean IL-8 production ± SEM.  Statistical analysis was performed 
using one-way ANOVA (P<0.001). Different letters denote significant differences 









































































Figure 12. IEC-6 IEC cultured with 40% v/v R0011 secretome (whole or <10 kDa 
fraction) or an HCl acidified control concurrently for 6 hours (n=6). Data shown are the 
mean CINC-1 production ± SEM.  Statistical analysis was performed using one-way 
ANOVA. There were no statistically significant differences between treatment groups. 








Figure 13. IEC-6 IEC cultured with 40% v/v R0389 secretome (whole or <10 kDa 
fraction) or an HCl acidified control concurrently for 6 hours (n=3). Data shown are the 
mean CINC-1 production ± SEM.  Statistical analysis was performed using one-way 
ANOVA. There were no statistically significant differences between treatment groups. 







Figure 14. IEC-6 IEC stimulated with Poly(I:C) and cultured with 40% v/v R0011 
secretome (whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 
hours (n=6). Data shown are the mean CINC-1 production ± SEM.  Statistical analysis 
was performed using one-way ANOVA. There were no statistically significant 









Figure 15. IEC-6 IEC stimulated with Poly(I:C) and cultured with 40% v/v R0389 
secretome (whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 
hours (n=3). Data shown are the mean CINC-1 production ± SEM.  Statistical analysis 
was performed using one-way ANOVA. There were no statistically significant 

















































































Figure 16. IEC-6 IEC stimulated with Flagellin and cultured with 40% v/v R0011 
secretome (whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 
hours (n=6). Data shown are the mean CINC-1 production ± SEM.  Statistical analysis 
was performed using one-way ANOVA (P<0.001). Different letters denote significant 

















































































Figure 17. IEC-6 IEC stimulated with Flagellin and cultured with 40% v/v R0389 
secretome (whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 
hours (n=3). Data shown are the mean CINC-1 production ± SEM.  Statistical analysis 
was performed using one-way ANOVA. There were no statistically significant 









































































Figure 18. IEC-6 IEC stimulated with LPS and cultured with 40% v/v R0011 secretome 
(whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 hours (n=3). 
Data shown are the mean CINC-1 production ± SEM.  Statistical analysis was performed 
using  one-way ANOVA (P<0.05). Different letters denote significant differences 






























































Figure 19. IEC-6 IEC stimulated with LPS and cultured with 40% v/v R0389 secretome 
(whole or <10 kDa fraction) or an HCl acidified control concurrently for 6 hours (n=3). 
Data shown are the mean CINC-1 production ± SEM.  Statistical analysis was performed 
using one-way ANOVA. There were no statistically significant differences between 









Figure 20. Lactic acid determination of both the Lactobacillus helveticus R0389 and the 
Lactobacillus rhamnosus R0011 secretomes. Data shown are the mean lactic acid 








Figure 21. ATP determination within both the Lactobacillus helveticus R0389 and the 
Lactobacillus rhamnosus R0011 secretomes. Data shown are the mean ATP 

























Figure 22. Constitutive CD73 expression on HT-29s. Data shown are the mean of the 
mean fluorescence intensity (MFI) ± SEM (n=3). Statistical analysis was performed using 
Graphpad Student’s t-test (P < 0.05). * indicates significance between groups. Cell 









Figure 23. Histogram analysis of constitutive CD73 expression on HT-29 IECs. CD73 
expression on HT-29 IEC (shown in red) is overlaid against the isotype control (shown in 
black). This is representative of four separate, independent experiments. The percent 






Figure 24. CD73 expression on HT-29s challenged with TNF-α ± <10 kDa fraction of 
the L. rhamnosus R0011 secretome or a lactic acid control. Data shown are the mean of 
the mean fluorescence intensity (MFI) ± SEM (n=3). Statistical analysis was performed 
using Graphpad Prism’s one-way ANOVA  (P > 0.05). There was no significant 







Figure 25. HT-29 IEC challenged with TNF-α ± <10 kDa fraction of the L. rhamnosus 
R0011 secretome or a lactic acid control concurrently with a selective CD73 blocker 
(Adenosine 5′-(α,β-methylene)diphosphate; 50µM) for 4 hours. Data shown are the mean 









































































































Figure 26. HT-29 IEC challenged with TNF-α ± <10 kDa fraction of the L. rhamnosus 
R0011 secretome or an HCl acidified control concurrently with an A2A receptor 



































































































Figure 27. HT-29 IEC challenged with TNF-α ± <10 kDa fraction of the L. rhamnosus 
R0011 secretome or an HCl acidified control concurrently with a PPARγ receptor 
antagonist (GW9662; 5 µM) for 6 hours. Data shown are the mean IL-8 production ± 





Figure 28. HT-29 IEC stimulated TNF-α and cultured with 40% v/v R0011 secretome 
(whole or <10 kDa fraction), pH neutralized R0011 secretome, or an HCl acidified 
control concurrently for 6 hours (n=3). Data shown are the mean IL-8 production ± SEM.  
Statistical analysis was performed using one-way ANOVA (P=0.0004). Different letters 
denote significant differences between treatment groups. Cell viabilities were greater than 





Figure 29. Growth of Salmonella typhimurium when cultured with the L. rhamnosus 
R0011 secretome over a 6 hour period. Data shown are the mean OD600 reading ± SEM 
(n=3). * denotes statistical differences between RPMI-grown S. typhimurium and the 
different treatment groups as determined using ANOVA (P = 0.001) and Dunnett’s 










Figure 30. Fermentation kinetics of differing starting inoculum sizes of L. rhamnosus 










Figure 31. Lactic acid determination of the L. rhamnosus R0011 milk ferments. Data 















































Figure 32. ATP determination within the L. rhamnosus R0011 milk ferment. Data shown 


































































































































Figure 33. IL-8 production by U937 monocytes pre-treated with L. rhamnosus R0011 
whole/filtered ferments or milk controls for 18 hours followed by stimulating with 125 
ng/mL LPS for 6 hours (mean IL-8 production ± SEM; n=3). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test.  Cell viabilities were > 





Figure 34. sCD54 production by U937 monocytes pre-treated with L. rhamnosus R0011 
whole/filtered ferments or milk controls for 18 hours followed by stimulating with 125 
ng/mL LPS for 6 hours (mean sCD54 production ± SEM; n=3). There was no statistical 
significance between treatment groups as determined using one-way ANOVA (P > 0.05).  
Cell viabilities were > 80% for all treatments as determined by XTT and Trypan Blue 






Figure 35. IL-1Ra production by U937 monocytes pre-treated with L. rhamnosus R0011 
whole/filtered ferments or milk controls for 18 hours followed by stimulating with 125 
ng/mL LPS for 6 hours (mean IL-1Ra production ± SEM; n=3). There were no statistical 
significance between treatment groups as determined using one-way ANOVA (P > 0.05).  
Cell viabilities were > 80% for all treatments as determined by the XTT and Trypan Blue 





Figure 36. IL-8 production by U937 monocytes stimulated with 125 ng/mL LPS and L. 
rhamnosus R0011 whole/filtered ferments or milk controls concurrently for 24 hrs (mean 
IL-8 production ± SEM; n=3). There were no significant differences between treatment 
groups as determined by one-way ANOVA (P > 0.05).  Cell viabilities were > 80% for 






Figure 37. sCD54 production by U937 monocytes stimulated with 125 ng/mL LPS and 
L. rhamnosus R0011 whole/filtered ferments or milk controls concurrently for 24 hrs 
(mean sCD54 production ± SEM; n=3). Different letters denote statistically significant 
differences between treatment groups as determined using one-way ANOVA (P < 0.05) 
and Tukey’s multiple comparison test. Cell viabilities were > 80% for all treatments as 






Figure 38. IL-1Ra production by U937 monocytes stimulated with 125 ng/mL LPS and 
L. rhamnosus R0011 whole/filtered ferments or milk controls concurrently for 24 hrs 
(mean IL-1Ra production ± SEM; n=3). There was no significant differences between 
treatment groups as determined by one-way ANOVA (P > 0.05).  Cell viabilities were > 





Figure 39. IL-8 production by THP-1 monocytes pre-treated with L. rhamnosus R0011 
whole/filtered ferments or milk controls for 18 hours followed by stimulating with 125 
ng/mL LPS for 6 hours (mean IL-8 production ± SEM; n=3). There was no significant 
differences between treatment groups as determined by one-way ANOVA (P > 0.05). 
Cell viabilities were > 80% for all treatments as determined by XTT and Trypan Blue 






Figure 40. sCD54 production by THP-1 monocytes pre-treated with L. rhamnosus R0011 
whole/filtered ferments or milk controls for 18 hours followed by stimulating with 125 
ng/mL LPS for 6 hours (mean sCD54 production ± SEM; n=3). There was no significant 
differences between treatment groups as determined by one-way ANOVA (P > 0.05). 
Cell viabilities were > 80% for all treatments as determined by XTT and Trypan Blue 






Figure 41. IL-1Ra production by THP-1 monocytes pre-treated with L. rhamnosus 
R0011 whole/filtered ferments or milk controls for 18 hours followed by stimulating with 
125 ng/mL LPS for 6 hours (mean IL-1Ra production ± SEM; n=3). There was no 
significant differences between treatment groups as determined by one-way ANOVA (P 
> 0.05). Cell viabilities were > 80% for all treatments as determined by XTT and Trypan 






Figure 42. IL-8 production by THP-1 monocytes stimulated with 125 ng/mL LPS and L. 
rhamnosus R0011 whole/filtered ferments or milk controls concurrently for 24 hrs (mean 
IL-8 production ± SEM; n=3). There was no significant differences between treatment 
groups as determined by one-way ANOVA (P < 0.05).  Cell viabilities were > 80% for 







Figure 43. sCD54 production by THP-1 monocytes stimulated with 125 ng/mL LPS and 
L. rhamnosus R0011 whole/filtered ferments or milk controls concurrently for 24 hrs 
(mean sCD54 production ± SEM; n=3). There was no significant differences between 
treatment groups as determined by one-way ANOVA (P < 0.05).  Cell viabilities were > 





Figure 44. IL-1Ra production by THP-1 monocytes stimulated with 125 ng/mL LPS and 
L. rhamnosus R0011 whole/filtered ferments or milk controls concurrently for 24 hrs 
(mean IL-1Ra production ± SEM; n=3). There was no significant differences between 
treatment groups as determined by one-way ANOVA (P < 0.05).  Cell viabilities were > 







Figure 45. CD11b expression on ATRA-differentiated U937 macrophages. Data shown 
are CD11b expression (mean fluorescence intensity, n=6). * denotes statistical 
significance between treatment groups as determined using student’s T-test (P = 0.0014). 












Figure 46. Histogram analysis of CD11b expression on U937 monocytes following 
differentiation with ATRA. CD11b expression by U937 cells treated with ATRA (shown 
in red) is overlaid with those cells which did not receive the ATRA treatment (shown in 
black). This is representative of six separate, independent experiments. The increase in 
the CD11b+ population following ATRA treatment was 45.9% as determined by the 


































































































































Figure 47. IL-10 production by  ATRA-differentiated U937 macrophages stimulated 
with 125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-10 production ± SEM; n=5). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test.  Cell viabilities were > 






























































































































Figure 48.  IL-1Ra production by ATRA-differentiated U937 macrophages stimulated 
with 125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-1Ra production ± SEM; n=4). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test.  Cell viabilities were > 





Figure 49. sCD54 production by ATRA-differentiated U937 macrophages stimulated 
with 125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean sCD54 production ± SEM; n=3). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test. Cell viabilities were > 





Figure 50. Total TGF-β production by ATRA-differentiated U937 macrophages 
stimulated with 125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk 
controls concurrently for 24 hrs (mean Total TGF-β production ± SEM; n=3). There was 
no significant differences between treatment groups as determined by one-way ANOVA 
(P < 0.05).  Cell viabilities were > 90% for all treatments as determined by Trypan Blue 





Figure 51. IL-8 production by ATRA-differentiated U937 macrophages stimulated with 
125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-8 production ± SEM; n=3). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test. Cell viabilities were > 





Figure 52. IL-6 production by ATRA-differentiated U937 macrophages stimulated with 
125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-6 production ± SEM; n=3). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test. Cell viabilities were > 





Figure 53. IL-1β production by ATRA-differentiated U937 macrophages stimulated with 
125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-1β production ± SEM; n=3). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test. Cell viabilities were > 





Figure 54. CD54 expression on ATRA-differentiated U937macrophages stimulated with 
125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean fluorescence intensity ± SEM; n=3). Different letters 
denote statistically significant differences between treatment groups as determined using 
one-way ANOVA (P < 0.05) and Tukey’s multiple comparison test. Cell viabilities were 


















Figure 55. CD11b expression on PMA-differentiated THP-1 macrophages. Data shown 
are CD11b expression (mean fluorescence intensity, n=6). * denotes  significant 
differences between treatment groups as determined using student’s T-test (P <0.05). Cell 












Figure 56. Histogram analysis of CD11b expression on THP-1 monocytes following 
differentiation with PMA. CD11b expression by PMA-treated THP-1 cells (shown in red) 
is overlaid with those cells which did not receive the PMA treatment (shown in black). 
This is representative of six separate, independent experiments. The increase in the 
CD11b+ population after PMA treatment was 59.9% as determined by the Overton 






Figure 57. IL-10 production by PMA-differentiated THP-1 macrophages stimulated with 
125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-10 production ± SEM; n=3). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test.  Cell viabilities were > 





Figure 58. sCD54 production by PMA-differentiated THP-1 macrophages stimulated 
with 125 ng/mL LPS and Lactobacillus rhamnosus R0011 whole/filtered ferments or 
milk controls concurrently for 24 hrs (mean sCD54 production ± SEM; n=3). There was 
no significant differences between treatment groups as determined by one-way ANOVA 
(P > 0.05).  Cell viabilities were > 90% for all treatments as determined by Trypan Blue 





Figure 59. IL-1Ra production by PMA-differentiated THP-1 macrophages stimulated 
with 125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-1Ra production ± SEM; n=3). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test.  Cell viabilities were > 





Figure 60. IL-8 production by PMA-differentiated THP-1 macrophages stimulated with 
125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-8 production ± SEM; n=4). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test.  Cell viabilities were > 





Figure 61. TNF-α production by PMA-differentiated THP-1 macrophages stimulated 
with 125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean TNF-α production ± SEM; n=3). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test.  Cell viabilities were > 





Figure 62. IL-6 production by PMA-differentiated THP-1 macrophages stimulated with 
125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-6 production ± SEM; n=3). Different letters denote 
statistically significant between treatment groups as determined using one-way ANOVA 
(P < 0.05) and Tukey’s multiple comparison test. Cell viabilities were > 90% for all 





Figure 63. IL-1β production by PMA-differentiated THP-1 macrophages stimulated with 
125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean IL-1β production ± SEM; n=3). Different letters denote 
statistically significant differences between treatment groups as determined using one-
way ANOVA (P < 0.05) and Tukey’s multiple comparison test. Cell viabilities were > 





Figure 64. Total TGF-β production by PMA-differentiated THP-1 macrophages 
stimulated with 125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk 
controls concurrently for 24 hrs (mean Total TGF-β production ± SEM; n=3). There was 
no significant differences between treatment groups as determined by one-way ANOVA 
(P > 0.05).  Cell viabilities were > 90% for all treatments as determined by Trypan Blue 





Figure 65. CD54 expression on PMA-differentiated THP-1 macrophages stimulated with 
125 ng/mL LPS and L. rhamnosus R0011 whole/filtered ferments or milk controls 
concurrently for 24 hrs (mean fluorescence intensity  ± SEM; n=3). Different letters 
denote statistically significant differences between treatment groups as determined using 
one-way ANOVA (P < 0.05) and Tukey’s multiple comparison test. Cell viabilities were 






L. rhamnosus R0011 and L. helveticus R0389 differentially modulated pro-
inflammatory chemokine production from human HT-29 and rat IEC-6 IECs 
Several species and strains of lactic acid bacteria have been characterised for their 
ability to modulate host immune responses through direct interactions with the mucosal 
immune system. Many of these bacteria have been classified as probiotic organisms 
defined as live microorganisms conferring health benefits to the host when consumed in 
adequate amounts (FAO/WHO, 2001). These microorganisms modulate host immune 
responses in response to pro-inflammatory challenges, antagonise the attachment of 
known-gut pathogens to IECs, improve gut epithelial barrier function, and improve 
dietary nutrient uptake (Bajaj et al., 2015).  However, the mechanisms used by many of 
these bacteria to exert these effects on the host remain unclear. Further, it is unknown 
whether these bacteria have to be in direct contact with host IECs or if they secrete 
bioactive molecules conferring immunological activity. As such, it is important to 
evaluate the range of bioactivity of these organisms and their products in order to 
elucidate potential mechanisms of action behind probiotic-induced effects on the host.   
The current study indicates that L. rhamnosus R0011 and L. helveticus R0389 
secrete a bioactive molecule (or molecules) of less than 10 kDa in size that attenuates 
pro-inflammatory chemokine production from challenged human HT-29 IECs. Further, 
the L. rhamnosus R0011 secretome and the less than 10 kDa fraction of the secretome 
decreased pro-inflammatory chemokine production from challenged rat IEC-6 IECs. 




producing bioactive molecules that act to dampen signals delivered through key PRRs 
and cytokine receptors associated with pro-inflammatory activity. This is in agreement 
with other studies suggesting that some probiotic microorganisms secrete bioactive 
molecules retaining immunomodulatory activity. For example, cell-free supernatants 
from L. kefir IM002 have been shown to significantly inhibit IL-8 production from HT-
29 IECs challenged with S. typhimurium (Carey and Kostrzynska, 2012). Bifidobacterium 
infantis and Lactobacillus acidophilus also secrete a bioactive molecule which down-
regulated IL-8 and IL-6 production from IL-1β and TNF-α challenged primary human 
enterocytes. Preliminary characterisation of the bioactive molecule found that it was less 
than 10 kDa in size and resistant to DNAse, RNAse, protease, heat, and acid treatment, 
although the precise nature of the bioactive molecule was not determined (Ganguli et al., 
2013).  
Other bacteria have been characterised for their ability to secrete bioactive 
molecules in culture which have immunomodulatory activity on cells of the innate 
immune system. For example, E. coli strain Nissle 1917 has been shown to produce a 
bioactive molecule that suppresses TNF-α-induced IL-8 production from human IECs in 
an NF-ĸB independent manner (Kamada et al., 2008).  The cell-free supernatant of L. 
rhamnosus CNCM I-4036 has also been shown to significantly down-regulate pro-
inflammatory cytokine production in human DCs challenged with E. coli. Treatment with 
the cell-free supernatant resulted in an increase in TLR-1 and TLR-5 gene transcription in 
DCs, suggesting a possible role of these TLRs in the observed immunomodulatory 




In contrast to the observed down-regulation of IL-8 production from challenged 
HT-29 IECs cultured with the L. helveticus R0389 secretome, there was no observed 
down-regulation of CINC-1 production from challenged IEC-6 IECs cultured with the 
secretome. Similarly, there was no observed down-regulation of poly (I:C)-induced 
CINC-1 production from IEC-6 IECs cultured with the L. rhamnosus R0011 secretome. 
This was the only instance in this study where the L. rhamnosus R0011 secretome did not 
down-regulate pro-inflammatory chemokine production from challenged IECs. These 
discrepancies between the observed immunomodulatory capacities of the secretomes 
between the two cell lines could be explained by differences between the species from 
which the cell lines were isolated or the location along the GI tract from which they 
originate. Another explanation may lie in the fact that the IEC-6 IEC cell line is a 
primary, non-transformed cell line while the HT-29 IECs were isolated from a colorectal 
adenocarcinoma. It has been noted that there are species- and tissue-specific responses to 
TLR stimulation (Rehli, 2002). For example, cells with myeloid lineage have been shown 
to respond in a NF-κB-independent manner when challenged with poly (I:C) while non-
myeloid cells do not (Lundberg et al., 2007). This suggests that there are multiple 
different signalling pathways which TLR-3 can activate. It is also important to note that 
TLR-3 signalling is mediated through a MyD88-independent pathway while the other 
TLR stimuli used in this study are mediated through the MyD88-dependent pathway. The 
results of this study suggests that the immunodulatory activity of the L. rhamnosus R0011 
secretome is effective only for signals mediated through the MyD88-dependent pathway 




ability to down-regulate CINC-1 production induced through the MyD88 independent 
pathway.   
Preliminary characterisation of the constituents of both L. rhamnosus R0011 and 
L. helveticus R0389 secretomes was conducted in an attempt to elucidate the nature of the 
bioactive molecule(s) present. Since commensal-derived ATP can potentially alter host 
immune function (Atarashi et al., 2008), the concentrations of ATP were measured in 
both secretomes.  It was found that both the L. rhamnosus R0011 and L. helveticus R0389 
secretomes contained ATP. It is unclear whether the ATP was secreted by the bacteria or 
released during bacterial cell lysis as cultures were harvested at stationary phase. 
Interestingly, the L. rhamnosus R0011 secretome contained an appreciably higher amount 
of ATP than that found in the L. helveticus R0389 secretome. Since ATP can be 
converted to the immunomodulatory molecule adenosine through the activity of CD73, 
CD73 expression was measured on HT-29 IEC and effects of incubation with the L. 
rhamnosus R0011 secretome were examined. Although CD73 expression was detected 
on HT-29 IEC, there were no significant changes in CD73 expression on HT-29 IEC 
following incubation with the R0011 secretome.  Pharmacological blocking of CD73 did 
not appear to reverse the immunomodulatory activity of the secretome at the 
concentrations examined in this study. Further, pharmacological blocking of the A2A 
adenosine receptor, the down-stream target of the liberated adenosine, did not appear to 
reverse the secretome’s immunomodulatory activity. Stimulation of HT-29 IEC with L. 
rhamnosus R0011 (using heat-killed bacteria) induces an increase in intracellular cAMP 




cAMP production and subsequent down-regulation of chemokine production from 
challenged IECs may not be mediated by ATP present within the secretome. 
L. rhamnosus R0011 predominantly secretes L(+)-lactic acid while L. helveticus 
predominantly secretes D(-)-lactic acid. L(+)-lactic acid has been attributed with 
immunosuppressive properties characterised by the ability to inhibit pro-inflammatory 
cytokine and chemokine production from human monocytes and dendritic cells. 
Interestingly, D(-)-lactic acid does not appear to have the same immunosuppressive 
effects,  as down-regulation of pro-inflammatory cytokine production was only seen in 
cells exposed to L(+)-lactic acid (Gottfried et al., 2006; Goetze et al., 2011). However, 
the effects of L(+)-lactic acid on IECs have not been extensively characterised. 
Preliminary analysis conducted at the time of writing has indicated that L(+)-lactic acid at 
a concentration similar to the concentration found in the L. rhamnosus R0011 secretome 
does not down-regulate TNF-α-induced IL-8 production from HT-29 IEC. Therefore, the 
observed down-regulation of IL-8 production in HT-29 IEC cultured with the L. 
rhamnosus R0011 or L. helveticus R0389 secretomes cannot be solely explained by the 
presence of lactic acid. 
In an attempt to identify down-stream molecular targets of the secretome, HT-29 
IEC were cultured with a PPARγ antagonist to determine whether the bioactivity of the 
secretome is mediated through this nuclear receptor. However, the addition of this 
antagonist did not reverse the ability of the R0011 secretome to down-regulate TNF-α-
induced IL-8 production from challenged HT-29 IEC. This suggests that the L. 
rhamnosus R0011 secretome may not activate the PPARγ receptor, and that the mode of 




down-regulate NF-κB activation through modulation of the PPARγ receptor (Kelly et al., 
2004; Eun et al., 2007; Bassaganya-Riera et al., 2012).  
To determine whether or not the immunomodulatory activities of the two 
secretomes could be attributed to indole production within culture, both the L. rhamnosus 
R0011 and L. helveticus R0389 were tested for their ability to produce indoles. Both 
strains tested negative for indole production when grown in MRS as determined by the 
traditional indole spot test suggesting that the immunomodulatory activity of the two 
secretomes is not mediated through AHRs as described by others (Zelante et al., 2013). 
However, the sensitivity of this test is low (Lombard and Dowell, 1983). High-
performance liquid chromatography should be used to validate these results to determine 
if indoles are indeed present within the two secretomes. 
Neutralisation of the pH of the L. rhamnosus R0011 secretome to physiological 
levels abrogated the observed down-regulation of IL-8 production from HT-29 cells 
challenged with TNF-α. This indicates that the bioactive molecule is pH sensitive and 
may provide a clue into its nature. However, it should be noted that sodium hydroxide 
was used to adjust the pH of the secretome. This is important as LTA has been shown to 
be sensitive to sodium hydroxide treatment (Ryu et al., 2009). LTA isolated from 
Enterococcus faecalis treated with sodium hydroxide or calcium hydroxide lost the 
ability to induce pro-inflammatory cytokine and nitric oxide production from RAW 264.7 
cells (Baik et al., 2011).  Interestingly, LTA isolated from some Gram positive bacteria is 
smaller than 10 kDa in size (Draing et al., 2006). Although not characterised within this 
study, LTA from some lactic acid bacteria have been shown to modulate IL-8 production 




Lactobacillus johnsonii La1 completely inhibited IL-8 production from TNF-α and LPS 
challenged HT-29 IEC. Deacylation of this LTA via treatment with ammonium 
hydroxide reversed the anti-inflammatory effect (Vidal et al., 2002).  
The less than 10 kDa fraction of the L. rhamnosus R0011 secretome also inhibited 
the growth of S. typhimurium. This inhibition was not observed when S. typhimurium was 
cultured with a HCl pH-control or a L(+)-lactic acid control suggesting that the L. 
rhamnosus R0011 secretes a class II bacteriocin with bacteriostatic properties. Class II 
bacteriocins are characterised as less than 10 kDa in size with the ability to inhibit the 
growth of several gut-associated pathogens (Todorov, 2009). In fact, L. johnsonii LA1 
and L. plantarum ACA-DC 287 significantly inhibit the growth of S. typhmurium by the 
production of an unknown inhibitory substance which is only active in the present of 
lactic acid (Makras et al., 2005). Further, Coconnier et al., (1997) have shown that the 
cell-free supernatant of L. acidophilus strain LB reduces the viability of several Gram-
positive and Gram-negative bacteria and reduces the infectivity of S. typhimurium in 
IECs in vivo, effects that the authors determined were not simply due to lactic acid 
(Coconnier et al., 1997). Dimitrijevic et al. (2009) have also shown that L. rhamnosus 
strain 68 secretes a 6433.8 Da peptide that inhibits the growth of Micrococcus 
lysodeikticus ATCC 4698,  but has no effect on the growth of L. plantarum 8014 or L. 
plantarum 39268 (Dimitrijevic et al., 2009). Interestingly, Sil, a bacteriocin produced by 
Streptococcus iniae, a common pathogen in fish, has been shown to not only antagonise 
the growth of Bacillus subtilis but also modulate host immune function in fish. Orally 
administered recombinant Sil reduced the oxidative burst capacity of monocytes in vivo, 




Collectively, the findings presented in this study illustrate that L. rhamnosus 
R0011 and L. helveticus R0389 secrete bioactive molecules retaining immunomodulatory 
activity, and that these bioactive molecules can down-regulate IL-8 production by human 
HT-29 IECs stimulated through varied PRRs or by pro-inflammatory cytokines. 
However, the two secretomes showed some differences in the ability to modulate TLR 
agonist-induced chemokine secretion; only the L. rhamnosus R0011 secretome was able 
to down-regulate CINC-1 production from rat IEC-6 cells challenged with flagellin or 
LPS, and neither the R0011 or the R0389 secretome significantly decreased  CINC-1 
production induced by poly (I:C). The bioactive secreted molecule appears to be less than 
10 kDa in size and is sensitive to pH neutralisation with sodium hydroxide. 
Milk fermented with L. rhamnosus R0011 has differential effects on pro-atherogenic 
and regulatory cytokine production from U937 and THP-1 human monocytes and 
macrophages 
 Probiotic-derived fermented products have become attractive functional foods for 
the delivery of probiotics and their biologically active products. The consumption of 
fermented dairy products has also been associated with immune system modulation, 
improved lactose digestion, alleviation of antibiotic-induced diarrhea, and reductions in 
serum cholesterol levels (Nagpal et al., 2012). It is currently unknown how these 
fermented dairy products confer their health benefits. Therefore, it is important to 
understand and elucidate the mechanisms behind these effects by examining the 




This study shows that milk fermented with L. rhamnosus R0011 has differential 
effects on cytokine production from challenged U937 and THP-1 human monocytes. Pre-
incubating U937 human monocyte cells with the filtered L. rhamnosus R0011 ferment 
and unfermented milk control prior to LPS challenge resulted in significantly higher 
levels of IL-8 production. This effect was not seen with THP-1 monocyte cells exposed 
to the same treatment. Previous studies have illustrated an immunostimulatory role of 
fermented milk consumption on human monocytes in vivo. Milk fermented with 
Lactobacillus casei DN114001 was shown to increase the oxidative burst capacity of 
monocytes in a cohort of healthy middle-aged adults (Parra et al., 2004). However, there 
were no changes in sCD54 or IL-1Ra production in either U937 or THP-1 monocytes in 
response to pre-incubation with L. rhamnosus R0011 milk ferments or milk controls.  
When U937 monocytes were cultured with the whole L. rhamnosus R0011 milk 
ferment and LPS, there was a significant down-regulation of sCD54 production. sCD54 is 
a soluble form of CD54 (ICAM-1) which has been associated with increased 
cardiovascular disease risk and has been recently used as a marker of chronic 
inflammation in atherosclerotic plaques (Witkowska and Borawska, 2004). This down-
regulation of sCD54 was also observed for U397 monocytes incubated with the whole 
lactic acid control and unfermented milk controls. Conversely, there was no effect of the 
L. rhamnosus R0011 ferment on LPS-induced sCD54 production by THP-1 monocytes. 
Further, there was no modulation of IL-1Ra or IL-8 production by either THP-1 or U937 
monocytes cultured with LPS and the L. rhamnosus R0011 ferments or milk controls. 
U937 and THP-1 monocytes were differentiated into macrophages in order to 




in atherosclerotic lesions.  Previous work has indicated differential effects of milk 
ferments on cytokine production and adhesion molecule expression by U937 cells at the 
monocyte and macrophage stages (Masotti et al., 2011).  Interestingly, there was an 
increase in IL-6 production by LPS-stimulated U937 macrophages cultured with the L. 
rhamnosus R0011 milk ferment which was not observed when LPS-stimulated cells were 
cultured with the filtered L. rhamnosus R0011 milk ferment or milk controls. Further, 
there was a significant increase production of the regulatory cytokine IL-10 by LPS-
stimulated U937 macrophages cultured with the L. rhamnosus R0011 milk ferment 
relative to those cells cultured with the whole lactic acid milk control and the 
unfermented milk control. Culturing of LPS-stimulated U937 macrophages with either 
the whole or filtered L. rhamnosus R0011 milk ferments also resulted in an increase in 
IL-1Ra production relative to the negative control. However, there was no modulation of 
sCD54, IL-8, IL-1β, TNF-α, IL-12p70 or TGF-β production from LPS-stimulated U937 
macrophages cultured with the L. rhamnosus R0011 milk ferments or milk controls and 
LPS.  THP-1 macrophages cultured with the whole L. rhamnosus R0011 milk ferment 
demonstrated an increase in LPS-induced IL-10 and IL-1β production. There were no 
changes in the production of LPS-induced IL-6, sCD54, IL-8, IL-1β, TNF-α, IL-12p70 or 
TGF-β. 
Taken together, it appears that milk fermented with L. rhamnosus R0011 
increases regulatory cytokine production from LPS challenged U937 and THP-1 
macrophages. The majority of these modulations in cytokine production were only 
observed in macrophages cultured with the whole L. rhamnosus R0011 ferment, and not 




required for the up-regulation of regulatory cytokine production. Indeed, there have been 
studies suggesting that probiotic Lactobacilli increase IL-10 and IL-6 production by 
murine macrophages through direct cell interactions (Morita et al., 2002) and these 
effects may be mediated through TLR-2 dependent activation of ERK (Kaji et al., 2010).  
Observed differences between THP-1 and U937 cells in response to culture with 
milk ferments and non-fermented milk controls may be explained by the differences in 
the tissue that these cells originate from and stage of maturation of cells at time of 
harvesting. THP-1 cells were isolated from a 1 year old patient suffering from an acute 
monocytic leukemia while U937 cells were isolated from a 37 year old suffering from a 
histiocytic lymphoma. As such, THP-1 cells often exhibit characteristics of less mature 
human peripheral blood monocyte cells while U937 cells are more representative of 
mature monocytic cells (Baek et al., 2009). Further, in vitro differentiation of THP-1 
cells has been shown to induce changes in gene expression which render THP-1 
macrophages more susceptible to food-derived compounds (Chanput et al., 2014). 
Further differences observed in the responses to the milk ferments between the two cell 
types could be explained by the different in vitro differentiation protocols used in this 
study. PMA differentiation of THP-1 cells in vitro increases NF-κB activation potentially 
resulting in a heightened sensitivity to stimuli (Chanput et al., 2014).   
These findings indicate that milk fermented with L. rhamnosus R0011 may 
polarise THP-1 and U937 macrophages into the immunoregulatory and atheroprotective 
M2b phenotype. This phenotype is characterised by the increased transcription of the 
regulatory cytokines IL-10 and IL-1Ra, with simultaneous transcription of pro-




commensal and pathogenic strains of bacteria can induce cytokine transcription profiles 
within resting macrophages suggesting polarization towards either the M1 or M2 
macrophage phenotype (Christoffersen et al., 2013; Isidro et al., 2014). However, further 
characterisation using cell surface markers is required to confirm polarization. 
Conclusion 
L. rhamnosus R0011 and L. helveticus R0389 secrete a bioactive molecule (or 
molecules) with immunomodulatory properties. This bioactive molecule was shown to 
down-regulate IL-8 production from challenged human HT-29 IEC and was shown to 
have differential effects on CINC-1 production from challenged rat IEC-6 cells, 
depending on the type of TLR agonist challenge. 
Milk fermented with L. rhamnosus R0011 appears to polarise resting THP-1 and 
U937 macrophages into the immunoregulatory M2b macrophage phenotype. This was 
characterised by the increased production of IL-10, IL-1Ra, IL-6, and IL-1β from both 
LPS-stimulated THP-1 and U937 macrophages cultured with L. rhamnosus R0011 milk 
ferments. These effects were only observed when cells were cultured with ferments 
containing live bacteria and not the filtered ferments containing the secreted products 
from  L. rhamnosus R0011 following growth in milk. 
Taken together, L. rhamnosus R0011 has immunomodulatory activity on two 
distinct cell types involved in innate immunity.  Although these effects are observed 
when R0011 is grown in different substrates, the requirement for microbe-cell contact 
observed for R0011 cultured in milk suggest a difference in the production of soluble 




gene and subsequent protein expression in lactic acid bacteria (Siragusa et al., 2014). It is 
currently unknown whether or not L. rhamnosus R0011 only produces the secreted 
bioactive molecule when grown in RPMI or if the THP-1/U937 macrophages are not 
affected by the secreted bioactive molecule. Filtered L. rhamnosus R0011 milk ferments 
have been shown to modulate prostaglandin production by IECs suggesting that bioactive 
molecules are released during the fermentation process (Fiander et al., 2003). This 
necessitates the need for cross-over studies examining the effects of RPMI-grown L. 
rhamnosus R0011 secreted products on challenged monocytes and macrophages and 
whole L. rhamnosus R0011 milk ferments on challenged IECs.  
Future Directions 
 In order to elucidate the molecular pathways which are being modulated by the L. 
rhamnosus and L. helveticus R0389 secretomes, transcriptional profiling of IECs exposed 
to the secretomes in response to pro-inflammatory challenge using whole-genome 
microarrays should be performed. Although effects on gene expression in resting HT-29 
IEC exposed to live L. rhamnosus R0011 have been reported with effects on genes 
involved in TLR and MAPK signalling (Audy et al., 2013), effects on TLR-agonist 
induced stimuli have not been examined to date. This will potentially allow for the 
delineation of the mechanisms of action of the secretomes and should focus on negative 
regulators of the innate immune system such as the A20 protein. Further characterisation 
of the bioactive constituents of the secretomes should also be carried out using a 
combination of high-performance liquid chromatography and matrix-assisted laser 
desorption/ionization time of flight mass spectrometry to identify any potential proteins 




unique proteins in L. rhamnosus R0011 which have been hypothesized to be secreted by 
the cell, only some have been annotated. These annotated proteins have been thought to 
be involved in binding to the mucin layer or fibronectin within the host (Kant et al., 
2014). This presents an intriguing area of future research to identify and annotate the 
remaining secreted proteins. If no proteins are found, gas chromatography-mass 
spectrometry should be used to identify other secreted products retaining 
immunomodulatory activity.  
Although this study has suggested that the L. rhamnosus R0011 milk ferments 
may polarize resting macrophages into the immunoregulatory and atheroprotective M2b 
phenotype, these experiments were done using established, transformed cell lines. In 
order to gain a more comprehensive understanding of the range of the bioactivity of the 
milk ferments on monocytes and macrophages, effects of the milk ferments should be 
tested on peripheral blood monocytes isolated from healthy individuals.  
Evaluation of the bioactivity of milk fermented with L. helveticus R0389 on the 
expression of pro-atherogenic biomarkers and macrophage polarization will also be 
useful. Milk fermented with L. helveticus R0389 has been shown to have 
immunomodulatory activity. Peptide fractions from milk fermented with L. helveticus 
R0389 promoted a Th2-mediated immunological response, characterised by an increase 
in IL-4, in vivo in rats infected with E. coli 0157:H7 (LeBlanc et al., 2004). Vinderola et 
al., (2007) have also shown that the milk fermented with L. helveticus R0389 modulates 
host immune responses within the gut by activating calcineurin (Vinderola et al., 2007). 
Additional studies will allow for direct comparisons between secreted products retaining 




Further characterisation of the bioactivity of L. rhamnosus R0011 and L. 
helveticus R0389 derived milk ferments should be carried out using a trans-well system 
consisting of human IECs and human monocytes or macrophages. This approach will 
allow for a more ideal simulation of the potential interactions between the L. rhamnosus 
R0011 and L. helveticus R0389 milk ferments and cells of the innate immune system. 
This system would also allow for the identification of bioactive proteins and molecules 
liberated during the fermentation process which can be transported across the IEC layer 
and modulate immune responses in the underlying monocytes or macrophages. It will 
also be interesting to see if the L. rhamnosus R0011 milk ferments can condition the IECs 
to produce regulatory cytokines which could down-regulate pro-inflammatory cytokine 
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Figure A1. Chemical configuration of L (+)-lactic acid and D(-) lactic acid. Images 
obtained from the Chemical Entities of Biological Interest database.  
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